SCODiA Report by MLBI Lab

Single-Cell Transcriptomic and Genomic Landscape of the Colorectal Cancer Microenvironment

This report provides a comprehensive single-cell analysis of the colorectal cancer (CRC) microenvironment, revealing extensive genomic instability, profound shifts in cellular composition, and dynamic reprogramming of cell-cell interactions and metabolic pathways. Intestinal epithelial cells, identified as the tumor-origin cell type, exhibit widespread aneuploidy and hyperactive proliferation. Immune and stromal cells undergo significant phenotypic adaptations, contributing to an immunosuppressive and pro-tumorigenic milieu. These findings offer critical insights into CRC pathogenesis and highlight numerous potential biomarkers and therapeutic targets for more effective clinical management.

Contents

0. Dataset overview
1. UMAP Visualization of Colon Cancer Single-Cell RNA-seq Data
2. Major Cell Type Score and Ploidy Distribution on UMAP
3. Marker Gene Expression Across Colonic Cell Subtypes
4. Copy Number Variation Analysis in Intestinal Epithelial Cells
5. UMAP Visualization of CNV Patterns across Cell Types, Ploidy, Condition, and Samples
6. Minor Cell Type Population Analysis in Colorectal Cancer
7. Population Analysis of T cell Subsets in Colorectal Cancer
8. Differential Abundance of T cell Subsets in Colorectal Cancer
9. Macrophage Subset Population Analysis in Colorectal Cancer
10. Differential Macrophage Subset Proportions in Colorectal Cancer
11. Ploidy Analysis of Intestinal Epithelial Cells in Colorectal Cancer
12. Cell-Cell Interaction Analysis in Colorectal Cancer: Contrasting Tumor and Adjacent Normal Microenvironments
13. Condition-Specific Cell-Cell Interaction Patterns in Colorectal Cancer
14. Condition-Specific Cell-Cell Interaction Patterns Involving Immune Checkpoint and Cell Cycle Pathways in Colorectal Cancer
15. Intestinal Epithelial Cell Condition-Specific Surfaceome Markers in Colorectal Cancer
16. Macrophage Condition-Specific Surfaceome Markers in Colorectal Cancer
17. Fibroblast Condition-Specific Surfaceome Marker Analysis in Colorectal Cancer
18. Condition-Specific Surfaceome Markers on CD4+ T cells in Colorectal Cancer
19. Elevated Cell Cycle Gene Expression Fraction in Intestinal Epithelial Cells of Colorectal Cancer
20. Gene Ontology (GSA) Analysis for Intestinal Epithelial Cells
21. Gene Set Enrichment Analysis (GSEA) of Colorectal Cancer Cell Types
22. Discussion
23. Query List

0. Dataset overview

Dataset Summary:

• The dataset is an AnnData object containing single-cell RNA-seq data from human Colon tissue, comprising 63,689 cells and 23,387 genes.
• Key observational metadata includes Patient, Class, Source, Sample, various cell type annotations (celltype_major, celltype_minor, celltype_subset), and ploidy information.
• Conditions studied are 'Tumor' and 'Adj_normal', with 'Adj_normal' serving as the reference condition for differential analyses.
• Identified cell type hierarchies include major, minor, and subset levels, covering various immune, stromal, and epithelial cell types.
• Ploidy analysis indicates 77.2% Diploid and 22.6% Aneuploid cells, with 'Intestinal Epithelial cell' resolved as the tumor-origin cell type.
• Copy Number Variation (CNV) estimates are available.
• Precomputed analysis results include Cell-Cell Interaction (CCI) data, Differential Expression Gene (DEG) results, Gene Set Enrichment Analysis (GSEA) results, and Gene Ontology (GSA/GO) results, all available for specific cell types and conditions.

1. UMAP Visualization of Colon Cancer Single-Cell RNA-seq Data

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Uniform Manifold Approximation and Projection (UMAP) plots generated from single-cell RNA-seq data, visualizing the cellular landscape of colon tissue. The UMAPs display cells colored by various metadata features, including condition, sample, celltype_major, celltype_minor, ploidy_dec, and celltype_subset. These visualizations are crucial for assessing data quality, validating cell type annotations, and understanding the overarching organizational structure of cells in the context of colorectal cancer.

Visual Summary

Condition

The UMAP colored by condition (Tumor vs. Adj_normal) shows a clear separation of cells primarily into two major regions. 'Tumor' cells (blue) broadly distribute across multiple distinct clusters, indicating significant cellular heterogeneity within the tumor microenvironment. 'Adj_normal' cells (maroon) also form distinct clusters, with some degree of intermingling with tumor cells in specific regions, but largely occupying separate areas of the UMAP space. This strong separation suggests profound transcriptional differences between the tumor and adjacent normal tissues.

Sample

The UMAP colored by sample reveals a generally good mixing of cells from different samples within their respective condition-specific clusters. While some smaller clusters may show a predominant contribution from one or a few samples, the major cell populations are composed of cells from multiple patients. This indicates that major batch effects associated with individual samples are not the primary drivers of the overall UMAP structure, suggesting effective data integration or minimal technical variation impacting global cell clustering.

Major Cell Type (celltype_major)

The celltype_major UMAP demonstrates that cells largely cluster according to their broad cell identities. Prominent clusters include 'Intestinal Epithelial cells' (orange), 'Stromal cells' (light blue/green), 'Myeloid cells' (yellow), and 'T cells' (dark blue), among others. 'Intestinal Epithelial cells' form a large, somewhat diffuse population, consistent with their role as the tumor-origin cell type and potential for significant transcriptional changes in cancer. Immune cell populations (e.g., T cells, B cells) form distinct, often tightly knit clusters, indicating robust identification of major immune components.

Minor Cell Type (celltype_minor)

The celltype_minor UMAP provides a finer resolution of cell identities, revealing more granular clustering patterns. For instance, T cell CD4+ and T cell CD8+ are clearly distinguished, as are different stromal components like Fibroblast and Endothelial cell. The overall clustering remains consistent with biologically meaningful cell groupings, reinforcing the quality of cell type annotation. Intestinal Epithelial cell again forms a large cluster, with subtle internal structure hinting at further epithelial subtypes.

Ploidy Status (ploidy_dec)

The ploidy_dec UMAP highlights a striking distribution of cell ploidy. 'Aneuploid' cells (maroon) predominantly localize within specific clusters, particularly overlapping with the large 'Intestinal Epithelial cell' population and other cells prominent in the 'Tumor' condition regions of the UMAP. 'Diploid' cells (yellow) are widely distributed across the embedding, representing the majority of cells in both normal and some tumor-associated immune/stromal populations. The 'Unclear' category (purple) represents a small fraction of cells that are scattered. This strong co-localization of aneuploidy with specific tumor-associated cell clusters, especially epithelial cells, strongly supports their neoplastic identity.

Cell Subtype (celltype_subset)

The celltype_subset UMAP provides the most detailed view of cellular heterogeneity. It further resolves populations like various T cell subsets (e.g., T cell (Th1), T cell (Treg), T cell (Cytotoxic)), macrophage subtypes (e.g., Macrophage (M1), Macrophage (M2A/B/C/D)), and specific epithelial cells (e.g., Goblet cell, Enterocyte, Paneth cell). This high-resolution annotation confirms the rich diversity of cell populations within the colon tissue and its tumor microenvironment, further validating the distinctness of these finely resolved cell types.

Biological Interpretation

The UMAP visualizations provide critical insights into the cellular composition and disease-associated changes in colorectal cancer:

• Disease-Specific Cellular Reorganization: The clear separation of 'Tumor' and 'Adj_normal' conditions in the UMAP indicates a fundamental shift in cellular states and proportions driven by the cancer. This global transcriptional divergence suggests that the tumor microenvironment is distinctly different from normal tissue, encompassing changes in both neoplastic cells and the surrounding immune and stromal components.
• Identification of Tumor-Origin Cells: The large, heterogeneous Intestinal Epithelial cell population that extensively overlaps with 'Aneuploid' cells and the 'Tumor' condition clusters strongly supports its identification as the tumor-origin cell type. Aneuploidy, a hallmark of cancer, is predominantly found within these epithelial cells, confirming their neoplastic transformation.
• Heterogeneity of the Tumor Microenvironment: The presence of diverse immune (T cells, B cells, Myeloid cells) and stromal (Fibroblast, Endothelial cell) populations, with many identified as specific subtypes, underscores the complexity and active nature of the tumor microenvironment. These non-malignant cells are known to play crucial roles in tumor progression, immunosuppression, and metastasis.
• Robust Cell Type Annotation: The consistent clustering of cells by their major, minor, and subset identities, with minimal mixing of distinct cell types, validates the quality and accuracy of the cell type annotations performed on this dataset. This reliable annotation is fundamental for downstream differential expression and pathway analyses.
• Minimal Batch Effects: The observed mixing of cells from different sample origins within biological clusters suggests that technical variability between samples has been largely mitigated or is not obscuring true biological variation, ensuring that observed differences are genuinely attributable to biological factors like condition or cell type.

Annotation Notes

The UMAP plots demonstrate a high quality of embedding and cell type annotation.

• Clarity of Annotation: The distinct separation of major, minor, and subset cell types across the UMAP space indicates that the assigned cell identities are well-resolved and transcriptionally distinct.
• Consistency of Features: The observed co-localization of 'Aneuploid' cells primarily within the 'Tumor' condition and specifically within the inferred 'Intestinal Epithelial cell' tumor-origin population provides strong internal consistency for the dataset's biological annotations.
• Absence of Dominant Batch Effects: The distributed representation of different samples across biological clusters suggests that patient-specific or technical batch effects are not overwhelming the biological signals. This supports the generalizability of findings across the sampled patients.

Overall, these UMAP visualizations affirm the quality of the single-cell data processing and the reliability of the cell type and ploidy annotations, providing a strong foundation for further in-depth analyses.

2. Major Cell Type Score and Ploidy Distribution on UMAP

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the distribution of major cell type scores and ploidy status across the single-cell RNA-seq UMAP embedding. For each major cell type, a score reflecting its transcriptional identity is overlaid on the UMAP, providing a gradient representation of cell type enrichment. Additionally, the ploidy status (Aneuploid, Diploid, Unclear) is mapped onto the UMAP, offering insight into chromosomal abnormalities within the cellular populations. These visualizations are crucial for evaluating the quality of cell type annotation and understanding the spatial organization of different cell populations, especially in the context of disease, such as the inferred Colorectal Cancer.

Visual Summary

The UMAP projections reveal a complex landscape of cellular populations, characterized by several distinct clusters.

Major Cell Type Scores (HiCAT_major_score):

• Each major cell type—T cell, B cell, Myeloid cell, Mast cell, Endothelial cell, Stromal cell, Enteric neuron, and Intestinal Epithelial cell—shows areas of high score concentration (yellow/green) corresponding to specific, well-separated clusters on the UMAP.
• Intestinal Epithelial cells exhibit a particularly strong and concentrated high score in the large, prominent cluster located at the bottom-center and a smaller adjacent cluster on the right side of the UMAP. This indicates a robust and distinct population.
• T cells and B cells show high scores in well-defined clusters primarily in the top-left region.
• Myeloid cells are concentrated in the upper-right cluster, while Stromal cells form a distinct cluster in the upper-central region.
• Endothelial cells and Mast cells also form relatively distinct, albeit smaller, clusters with high scores.
• Enteric neuron scores are generally low across the UMAP, with only a few sparse cells showing slightly elevated scores, suggesting it is a rare or less transcriptionally distinct population in this dataset.
• When compared to the celltype_major plot, the score distributions generally align very well with the discrete cell type assignments, confirming the specificity of the major cell type scores.

Ploidy Status (ploidy_dec):

• Aneuploid cells (red) are predominantly localized to the large, bottom-center cluster which corresponds directly to the Intestinal Epithelial cell population. Smaller pockets of aneuploid cells are also observed in other areas, but the primary concentration is within the epithelial compartment.
• Diploid cells (yellow) constitute the majority of cells across most other clusters, including those identified as T cells, B cells, Myeloid cells, Stromal cells, and Endothelial cells.
• Unclear cells (purple) are very few and scattered, indicating a low ambiguity rate in ploidy determination.

Biological Interpretation

The visualization effectively delineates the major cellular components of the colon tissue, providing critical insights into the inferred Colorectal Cancer context.

1. Tumor Cell Identification: The Intestinal Epithelial cell population, which has been resolved as the "tumor-origin cell type," forms a large, distinct cluster with a high corresponding HiCAT_major_score. Crucially, this same cluster exhibits a very high proportion of Aneuploid cells. Aneuploidy, the presence of an abnormal number of chromosomes, is a well-established hallmark of cancer cells [NCBI]. This strong co-localization of high epithelial cell identity scores with aneuploidy provides compelling evidence that this epithelial cluster represents the malignant tumor cells.
2. Tumor Microenvironment Composition: The remaining clusters, largely characterized by diploid cells, represent the diverse components of the tumor microenvironment. These include various immune cells (T cells, B cells, Myeloid cells, Mast cells) and stromal cells (Fibroblasts, Endothelial cells). Their distinct segregation on the UMAP highlights the cellular heterogeneity within the tumor and its surrounding tissue, a key feature in cancer biology. The relative abundance and spatial arrangement of these immune and stromal cell types within the tumor microenvironment are known to influence tumor progression and therapeutic response in colorectal cancer [PubMed Search].
3. Annotation Quality and Consistency: The strong agreement between the continuous HiCAT_major_score distributions and the discrete celltype_major labels indicates robust and accurate cell type annotation. Each major cell type forms well-separated clusters, suggesting distinct transcriptional profiles that were effectively captured and annotated. The clear distinction between aneuploid tumor cells and diploid non-tumor cells further validates the integrated analytical approach of combining gene expression-based cell typing with ploidy estimation.

Annotation Notes

• The HiCAT_major_score plots confirm that the major cell type annotations are generally robust, with distinct populations showing high scores for their assigned identities. This provides a high level of confidence in the celltype_major assignments.
• The UMAP visualization clearly differentiates the presumed malignant Intestinal Epithelial cells (marked by high aneuploidy) from the surrounding immune and stromal cells, which are predominantly diploid. This separation is critical for downstream analyses focusing on tumor-specific biology.
• The low and diffuse scores for Enteric neuron suggest that this cell type is either rare, less transcriptionally distinct in this dataset, or may not form a cohesive cluster. Further investigation into minor or subset cell types could provide more granular resolution for such populations.
• Overall, the visualization supports the quality of both cell type annotation and ploidy inference, providing a solid foundation for deeper biological investigation into colorectal cancer mechanisms.

3. Marker Gene Expression Across Colonic Cell Subtypes

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot illustrating the expression of identified marker genes across various celltype_subset populations within the human Colon single-cell RNA-seq dataset. The plot serves as a critical visualization for validating the distinctness and biological fidelity of the assigned cell annotations. Each row represents a specific cell celltype_subset, while columns represent individual marker genes grouped by the cell type they are predominantly associated with. The size of each dot indicates the fraction of cells within that group expressing the gene, and the color intensity (from light red to dark red) represents the mean expression level of the gene in that cell group.

Visual Summary

The dot plot displays a clear and organized pattern of marker gene expression, with distinct clusters of highly expressed genes corresponding to specific cell celltype_subset populations. This "block-like" diagonal pattern, particularly evident for many cell types, strongly suggests that the chosen markers effectively differentiate the various cell populations.

Key visual observations include:

• Distinct Cell Type Signatures: Many cell celltype_subset groups show unique and strong expression of a set of marker genes, indicating robust and well-defined identities. For instance, Enterocyte, Fibroblast, Goblet cell, Lymphatic Endothelial cell, Macrophage subtypes, Plasma cell, and Smooth muscle cell each exhibit highly specific marker gene profiles.
• Expression Levels and Prevalence: Darker red colors signify higher mean expression, while larger dot sizes indicate a higher percentage of cells within the group expressing the gene. Most specific markers show both high mean expression and high prevalence within their designated cell type.
• Shared Markers: Some genes show expression across related cell types, which is biologically expected. For example, JCHAIN and MZB1 are highly expressed in both B cell (MZ) and Plasma cell, consistent with their roles in B cell lineage and antibody production. Similarly, ILCs and some T cells share markers like GATA3, CD44, and CD7.
• Subtype Differentiation: Within broader cell categories (e.g., Dendritic cells, Macrophages, T cells), the plot highlights markers that help distinguish subtypes. For instance, IRF7 and LILRA4 are prominent for DC (Plasmacytoid), while CD83, IRF4, and IRF8 are characteristic of DC (Classical). Distinct T cell subtypes like T cell (Cytotoxic) show GZMB expression, T cell (Th1) shows STAT4, and T cell (Th17) shows RORA.
• Underlying Structure: The rotation of gene names (as per var_group_rotation = 45) allows for clear labeling of the numerous markers, and the overall layout facilitates quick identification of cell type-specific gene sets.

Biological Interpretation

The observed marker gene expression patterns strongly support the biological identity of the celltype_subset annotations, consistent with known cellular populations in the colon and general immunology.

Intestinal Epithelial Cells:

• Crypt cells show high expression of ASCL2, EPHB2, and AXIN2, which are known markers for intestinal stem cells and progenitor cells residing in the crypts, crucial for epithelial regeneration.
• Enterocytes are characterized by a broad set of markers including FABP1, CDH17, CDX1, KLF5, VIL1, FERMT1, ACSL5, ABHD11, PDHA1, and CDX2. These genes are involved in nutrient absorption, epithelial cell differentiation, and maintaining gut barrier function. GeneCards: FABP1
• Goblet cells exhibit strong expression of MUC13, TFF3, and AGR2, which are associated with mucin production and secretion, essential for intestinal protection. GeneCards: MUC13
• Paneth cells express DEFA5 and CD55, indicative of their role in antimicrobial peptide secretion and immune defense.

Immune Cells:

• B cell (MZ) and Plasma cells distinctly express POU2F2, JCHAIN, and MZB1. JCHAIN is particularly strong in plasma cells, indicating their active role in immunoglobulin production. UniProt: JCHAIN
• Dendritic cells are well-differentiated: DC (Classical) markers like CD83, IRF4, and IRF8 are involved in antigen presentation, while DC (Plasmacytoid) markers such as IRF7 and LILRA4 indicate their role in antiviral immunity and interferon production.
• Macrophages (M1, M2A, M2B, M2C) show shared markers like MSR1, SOCS3, C1R, and C1S, consistent with their phagocytic and immune regulatory functions. While specific markers for fine M2 subtype differentiation might be subtle in this overview, the general macrophage identity is clear.
• Mast cells are marked by TPSB2, TPSAB1, and SRGN, highlighting their role in immediate hypersensitivity and inflammatory responses. GeneCards: TPSB2
• T cells and ILCs display distinct subtype markers. T cell (Cytotoxic) shows GZMB (granzyme B), a key effector molecule. T cell (Th1) is marked by STAT4, T cell (Th17) by RORA, reflecting their respective transcriptional programs. ILC1 and ILC2 show GATA3 and IL2RG, affirming their roles as innate lymphoid cells.

Stromal and Endothelial Cells:

• Fibroblasts express extracellular matrix components like COL1A1, COL1A2, COL3A1, DCN, and LUM, consistent with their role in tissue structure and repair.
• Endothelial tip cells show ANGPT2 and DLL4, crucial for angiogenesis.
• Lymphatic Endothelial cells are identified by PROX1 and PDPN, involved in lymphatic vessel formation and function.
• Smooth muscle cells exhibit ACTA2, MYH11, and TAGLN, which are contractile proteins fundamental to muscle function.

Annotation Notes

The comprehensive display of marker gene expression across celltype_subset groups provides strong evidence for the accuracy and robustness of the cell type annotations. The distinct and expected expression profiles for most cell types, particularly the clear blocks of specific markers, validate their assigned identities. While some closely related cell types might share general lineage markers, the presence of differentiating genes allows for their reliable resolution. This analysis confirms that the celltype_subset labels are biologically meaningful and well-supported by the underlying gene expression data.

4. Copy Number Variation Analysis in Intestinal Epithelial Cells

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates Copy Number Variations (CNVs) within the "Intestinal Epithelial cell" population, identified as the resolved tumor-origin cell type in this single-cell RNA-seq dataset from human Colon tissue. The primary goal is to visualize CNV patterns across different samples, grouped by sample and condition (Tumor vs. Adjacent Normal), and to summarize regions exhibiting significant copy number amplifications. This helps in validating the tumor status of samples and understanding genomic instability within the tumor-derived cell population, consistent with the inferred context of Colorectal Cancer.

Visual Summary: CNV Heatmap

The heatmap displays log2(CNR) (Copy Number Ratio) values across genomic spots for Intestinal Epithelial cells, grouped by individual samples.

• Differential Patterns by Condition: A clear distinction is observed between "Adj_normal" (SMCxx-N) and "Tumor" (SMCxx-T) samples. The "Adj_normal" samples predominantly show a relatively flat, close-to-zero log2(CNR) profile, indicating a largely diploid genome, with minimal widespread amplifications (red) or deletions (blue). In contrast, "Tumor" samples exhibit numerous and widespread regions of both amplifications (red/yellow) and deletions (blue) across multiple chromosomes, signifying significant genomic instability.
• Sample Heterogeneity: While all tumor samples show CNVs, there's notable heterogeneity in the specific patterns and magnitudes of alterations between different tumor samples. Some samples, like SMC04-T, SMC06-T, and SMC07-T, appear to have more pronounced and widespread CNV events compared to others, such as SMC19-T or SMC21-T, which might indicate differences in tumor stage, aggressiveness, or clonal evolution.
• Common Alterations: Despite heterogeneity, certain regions appear frequently altered across multiple tumor samples. For instance, amplifications are often observed on regions of chromosomes 7, 8, and 20, while deletions can be seen on parts of chromosome 18. These recurrent patterns may point to critical driver events in colorectal cancer progression.
• Chromosomal Architecture: The heatmap clearly demarcates individual chromosomes (chr1 through chr22), with cytogenetic bands indicated at the top, allowing for precise localization of CNV events. The yellow shaded regions on the heatmap correspond to the locations where specific cytogenetic bands are labeled, facilitating correlation with the summary of amplified regions.

Interpretation of Amplified Regions Summary

The second plot provides a summary of regions with significantly amplified copy numbers, presented as a heatmap showing the magnitude/frequency of amplification per cytogenetic band across tumor samples, along with a bar chart indicating the overall frequency of these amplifications.

• Prevalent Amplifications: Several cytogenetic bands show consistent amplification across multiple tumor samples. Notably:
  • 1q21.3:1q23.2 (Frequency ~0.6) and 20q35:2q36.3 (Frequency ~0.6) show moderate to high amplification across many tumor samples.
  • 7p13:7q11.23 (EGFR) stands out with a frequency of 0.50. This region, encompassing the *EGFR* gene, shows strong amplification in samples like SMC01-T, SMC02-T, SMC03-T, SMC04-T, SMC06-T, and SMC07-T, with magnitudes often exceeding 1.0 (e.g., 3.8 in SMC07-T, 2.8 in SMC06-T), indicating significant gene dosage increases.
  • 8p21.1:8q24.1 (GSDMD, TPD52, EIF3E, INTS8) is frequently amplified (frequency ~0.59), particularly in samples such as SMC01-T, SMC02-T, SMC03-T, SMC04-T, SMC06-T, SMC07-T, SMC11-T, SMC14-T, SMC15-T, SMC17-T, SMC23-T, and SMC24-T. The genes listed (GSDMD, TPD52, EIF3E, INTS8) are located within this amplified region.
  • 19p13:19q13.13 (Frequency ~0.77) also shows widespread amplification across many tumor samples, including SMC01-T, SMC02-T, SMC03-T, SMC04-T, SMC06-T, SMC07-T, SMC08-T, SMC09-T, SMC10-T, SMC11-T, SMC14-T, SMC15-T, SMC16-T, SMC17-T, SMC23-T, SMC24-T, and SMC25-T.
• Sample-Specific Amplifications: While some regions are recurrent, other amplifications are more sample-specific, contributing to the observed inter-sample heterogeneity. For example, SMC01-T, SMC03-T, SMC04-T, SMC06-T, and SMC07-T consistently show the highest number and magnitude of amplifications across the reported bands.

Biological Interpretation

The observed CNV patterns in Intestinal Epithelial cells strongly support their identification as the tumor-origin cell type and align with characteristics of Colorectal Cancer.

• Genomic Instability in Cancer: The extensive and heterogeneous CNVs in tumor samples, in contrast to the stable genomes in adjacent normal samples, are hallmarks of cancer. This genomic instability can drive tumor evolution and therapeutic resistance.
• EGFR Amplification: The recurrent amplification of the 7p13:7q11.23 region, which includes the *EGFR* gene, is highly significant. Epidermal Growth Factor Receptor (EGFR) is a well-established oncogene in Colorectal Cancer, and its amplification or overexpression is a common event, contributing to uncontrolled cell proliferation, survival, and metastasis. EGFR inhibitors are a class of targeted therapies for CRC, and *EGFR* amplification can predict response or resistance to these treatments [PubMed Search: EGFR amplification colorectal cancer].
• 8q21.1:8q24.1 Amplification: This region contains several genes of interest.
  • *GSDMD* (Gasdermin D) plays a role in pyroptosis, a form of programmed cell death. Its amplification in cancer can have complex effects on tumor progression and immune response [PubMed Search: GSDMD cancer].
  • *TPD52* (Tumor Protein D52) is an oncogene frequently overexpressed in various cancers, including CRC, involved in cell proliferation and survival [GeneCards: TPD52].
  • *EIF3E* (Eukaryotic Translation Initiation Factor 3 Subunit E) is part of a complex involved in protein synthesis, and its dysregulation is linked to cancer development [GeneCards: EIF3E].
  • *INTS8* (Integrator Complex Subunit 8) is a component of the Integrator complex, involved in snRNA processing and gene expression regulation. Its role in cancer is emerging [GeneCards: INTS8]. The amplification of this region suggests potential contributions to altered cellular processes vital for cancer growth.
• 19p13:19q13.13 Amplification: Recurrent amplification of this region also points to potential oncogenic drivers or genomic vulnerabilities within this chromosomal area that contribute to CRC pathogenesis.
• Tumor Heterogeneity: The variability in CNV profiles across different tumor samples underscores the genetic heterogeneity within CRC, which has implications for diagnosis, prognosis, and treatment strategies. Each tumor may harbor a unique combination of genomic alterations.

Annotation Notes

• The CNV analysis provides strong validation for the "Tumor" versus "Adj_normal" classification of samples and for the resolution of "Intestinal Epithelial cell" as the tumor-origin cell type. The clear distinction in genomic instability between the two conditions within this specific cell type confirms that these are indeed the malignant cells.
• The identification of prevalent aneuploidy in Intestinal Epithelial cells from tumor samples directly correlates with the 22.6% of cells initially labeled as 'Aneuploid' in the dataset, further strengthening the confidence in the cell ploidy and tumor classification annotations.
• The grouping by 'sample' effectively highlights inter-patient variability in tumor genomics, which is a crucial aspect of personalized medicine.

5. UMAP Visualization of CNV Patterns across Cell Types, Ploidy, Condition, and Samples

[Analysis Visualization Results]...

Analysis Overview

This analysis presents UMAP (Uniform Manifold Approximation and Projection) visualizations based on Copy Number Variation (CNV) patterns for 63,689 single cells from human colon tissue. The UMAP plots are colored by different metadata features: major cell type (celltype_major), minor cell type (celltype_minor), ploidy status (ploidy_dec), sample condition (condition), and individual sample (sample). The UMAP embedding itself is computed using CNV data, meaning the spatial relationships between cells in the plots reflect similarities in their genomic CNV profiles. This allows for an assessment of how well these biological and experimental variables align with underlying CNV heterogeneity, particularly in the context of colorectal cancer as inferred from the dataset.

Visual Summary

The UMAP plots reveal distinct clustering patterns driven by CNV, which correspond strongly with cell type, ploidy status, and condition.

celltype_major and celltype_minor

• A prominent, large cluster is observed on the right side of the UMAP, primarily composed of Intestinal Epithelial cell (major cell type, light orange in celltype_major plot). This cluster shows further substructure when colored by celltype_minor, suggesting heterogeneity within the epithelial compartment.
• Distinct smaller clusters or regions are visible for immune cells such as T cell (blue/light blue), B cell (dark red), and Myeloid cell (green), primarily located in the upper-left and bottom-left regions of the main epithelial cluster. Stromal cell (light green) and Endothelial cell (red) also form relatively distinct clusters, often flanking the main epithelial body.
• There is also a separate, smaller cluster of cells to the far left, which appears to be Enteric neuron (orange) and Enteric glial cell (light orange) in the minor cell type plot, indicating their unique CNV profiles.

ploidy_dec

• A clear separation is observed between Diploid (yellow) and Aneuploid (dark red) cells. The vast majority of Diploid cells form a large, diffuse cluster towards the top and center-right of the UMAP.
• Aneuploid cells form a more compact, distinct cluster primarily in the bottom-left and central regions, showing a strong spatial segregation from the Diploid cells. There are also smaller, isolated Aneuploid clusters. The Unclear (purple) cells are very sparse and scattered.

condition

• The Tumor (purple) and Adj_normal (dark red) conditions also show strong segregation, mirroring the ploidy_dec plot.
• The Tumor cells largely overlap with the Aneuploid cell clusters, occupying the bottom-left and central regions of the main UMAP body.
• The Adj_normal cells predominantly overlap with the Diploid cell clusters, located towards the top and center-right. This indicates a strong correlation between the tumor condition and the presence of aneuploidy.

sample

• The sample plot reveals that cells from different samples (e.g., SMC01-T, SMC02-T, etc.) are generally well-interspersed within their respective Tumor or Adj_normal condition clusters.
• While some samples show localized enrichment within the main Tumor or Adj_normal regions, there are no overtly strong sample-specific clusters that would suggest a significant batch effect dominating the overall CNV-based UMAP structure. The 'T' (Tumor) and 'N' (Adj_normal) suffixes for samples often cluster distinctly, reinforcing the condition-specific separation.

Biological Interpretation

The CNV-driven UMAP provides compelling insights into the cellular landscape of colorectal cancer. The strong separation of Aneuploid cells from Diploid cells, and their almost complete overlap with cells from Tumor conditions, strongly supports the identification of these Aneuploid cell populations as malignant. Given that Intestinal Epithelial cell has been resolved as the tumor-origin cell type, the concentration of Aneuploid cells within the Intestinal Epithelial cell cluster is a key finding, reinforcing their identity as cancerous epithelial cells. This suggests that the primary malignant component of the tumor originates from and maintains epithelial characteristics, but with significant genomic instability reflected in their aneuploid status.

The observation that Adj_normal cells are largely Diploid and segregate distinctly from Tumor cells confirms the expected genomic stability in normal tissue counterparts. The presence of other cell types (immune cells, stromal cells, endothelial cells, enteric neurons/glia) in both Tumor and Adj_normal contexts, largely outside the main Aneuploid cluster, indicates their expected roles in the tumor microenvironment or as non-malignant tissue components. The distinct clustering of these non-epithelial cell types, even when some might be found in the tumor context, suggests that their CNV profiles remain largely diploid or stable compared to the highly altered cancerous epithelial cells. The UMAP effectively captures the profound genomic alterations characteristic of cancer, specifically highlighting the aneuploidy of the tumor-origin epithelial cells as a primary driver of cellular heterogeneity and clustering in this dataset.

Annotation Notes

The UMAPs demonstrate excellent separation and clear biological interpretability based on CNV patterns.

• Cell Type Annotation Quality: The distinct clustering of major and minor cell types suggests high quality and consistency in cell type annotation, as these labels align well with inherent CNV differences. The Intestinal Epithelial cell population, identified as the tumor-origin cell type, forms a large and heterogenous cluster, consistent with the expected complexity of tumor cells.
• Ploidy and Condition Consistency: The striking segregation of Aneuploid cells from Diploid cells, and their direct correspondence with Tumor and Adj_normal conditions respectively, validates the robustness of both the ploidy estimation and the condition labels within the dataset.
• Embedding Structure: The CNV-based UMAP effectively captures fundamental genomic differences, successfully separating distinct cell populations based on their copy number profiles. The clear visual separation provides strong evidence for the biological validity of the annotations.
• Sample Distribution: The lack of overt sample-specific batch effects, where cells from different patients mix within their respective condition/ploidy clusters, indicates that the observed biological differences are generally conserved across samples and not artifacts of experimental processing or individual patient variation overriding the core CNV signal.

6. Minor Cell Type Population Analysis in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a stacked bar plot visualizing the proportional distribution of minor cell types across individual samples, categorized by their condition: "Adj_normal" (adjacent normal tissue) and "Tumor". The primary goal is to identify shifts in cell type composition within the tumor microenvironment compared to healthy adjacent tissue, providing insights into the cellular landscape of colorectal cancer.

Visual Summary

The visualization displays the relative abundance of 14 minor cell types identified in the dataset for each sample. Samples are grouped by condition, with 'Adj_normal' samples on the left and 'Tumor' samples on the right.

1. Intestinal Epithelial Cell Dominance in Tumor: A striking feature is the substantially increased proportion of "Intestinal Epithelial cell" (light yellow bar segment) in most 'Tumor' samples compared to 'Adj_normal' samples. In many tumor samples (e.g., SMC01-T, SMC09-T, SMC16-T, SMC21-T, SMC18-T, SMC22-T), Intestinal Epithelial cells constitute a large majority (often >60-80%) of the total cell population. This is consistent with the tumor-origin cell type being resolved as 'Intestinal Epithelial cell'.
2. Reduction of Immune Cells in Tumor: Conversely, the relative proportions of certain immune cell types, particularly "T cell CD4+" (teal) and "T cell CD8+" (dark blue), appear visibly reduced in many 'Tumor' samples where Intestinal Epithelial cells are dominant. In 'Adj_normal' samples, these T cell populations, along with other immune cells like "B cell" (dark red), collectively form a larger fraction of the cellular composition.
3. Variability within Tumor Samples: There is considerable heterogeneity in cell type composition among the 'Tumor' samples. While some tumor samples are highly enriched for Intestinal Epithelial cells, others (e.g., SMC06-T, SMC07-T, SMC08-T, SMC15-T, SMC04-T) show a more diverse composition, including substantial proportions of "Fibroblast" (light orange) and various immune cells.
4. Stromal Components: "Fibroblast" cells consistently contribute to both 'Adj_normal' and 'Tumor' samples, though their relative proportion appears more variable in tumor samples, possibly indicating varying degrees of stromal infiltration or desmoplasia. "Endothelial cell" (orange-red) and "Smooth muscle cell" (light green) are present in smaller, yet consistent, proportions across most samples.
5. Other Immune Cells: "Macrophage" (pale yellow) proportions are variable, sometimes constituting a notable fraction in both conditions, but without a clear trend of consistent increase or decrease across all tumor samples. "Plasma cell" (light green) and "B cell" (dark red) also show variability, but their overall contribution seems less pronounced in tumor samples with high epithelial content.

Biological Interpretation

The observed shifts in cell type populations provide crucial biological insights into the colorectal cancer microenvironment:

• Tumor Growth and Intestinal Epithelial Cell Expansion: The significant expansion of "Intestinal Epithelial cells" in tumor samples is a direct reflection of neoplastic proliferation. As these are identified as the tumor-origin cells, their increased abundance is expected in cancerous lesions, representing the malignant component of the tumor.
• Immune Landscape Alterations and Evasion: The apparent decrease in "T cell CD4+" and "T cell CD8+" populations in many tumor samples suggests potential immune evasion mechanisms at play. A reduction in anti-tumor immune cells within the tumor microenvironment (TME) can indicate an "immune desert" or "immune excluded" phenotype, which are associated with poor prognosis and resistance to immunotherapy in colorectal cancer [1].
• Tumor Microenvironment Heterogeneity: The variability in cell composition among tumor samples highlights the intrinsic heterogeneity of colorectal cancer. Some tumors may be highly epithelial-rich (pure tumor mass), while others are more infiltrated with immune and stromal cells, reflecting different immune phenotypes or stages of tumor progression.
• Role of Stromal Cells: The presence and variability of "Fibroblast" populations (likely Cancer-Associated Fibroblasts or CAFs) further underscore their important role in shaping the TME. CAFs contribute to extracellular matrix remodeling, create an immunosuppressive environment, and support tumor growth and metastasis [2].
• Inferred Disease Context Validation: The cell type changes, particularly the dominance of Intestinal Epithelial cells and altered immune cell proportions in 'Tumor' samples, strongly support the inferred biological context of Colorectal Cancer, where epithelial cells undergo malignant transformation and interact extensively with immune and stromal components.

Clinical or Translational Implications

Understanding these cell population shifts has several clinical and translational implications for colorectal cancer:

• Biomarker for Tumor Purity/Composition: The proportion of Intestinal Epithelial cells can serve as an indicator of tumor cellularity, which is relevant for molecular profiling and drug response studies.
• Immunotherapy Response Prediction: Tumors with a low infiltration of T cells (especially CD8+) might be less responsive to immunotherapies that rely on T cell activation. Identifying these "immune desert" or "immune excluded" phenotypes could help stratify patients for appropriate treatment strategies [3].
• Targeting the Tumor Microenvironment: The consistent presence of fibroblasts suggests that targeting the stromal compartment, specifically CAFs, could be a viable therapeutic strategy to disrupt tumor growth and enhance immune infiltration.
• Prognostic Significance: The specific cellular composition of the tumor microenvironment, particularly the balance between tumor cells, immune cells, and stromal cells, often correlates with patient prognosis in colorectal cancer.

---

References:

1. Immune evasion in colorectal cancer: PubMed search for "colorectal cancer immune evasion T cells" https://pubmed.ncbi.nlm.nih.gov/?term=colorectal+cancer+immune+evasion+T+cells
2. Cancer-associated fibroblasts in CRC: PubMed search for "colorectal cancer associated fibroblasts" https://pubmed.ncbi.nlm.nih.gov/?term=colorectal+cancer+associated+fibroblasts
3. T cell infiltration and immunotherapy: PubMed search for "tumor infiltrating lymphocytes colorectal cancer immunotherapy" https://pubmed.ncbi.nlm.nih.gov/?term=tumor+infiltrating+lymphocytes+colorectal+cancer+immunotherapy

7. Population Analysis of T cell Subsets in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis presents population bar plots depicting the relative proportions of T cell subsets, NK cells, and Innate Lymphoid Cells (ILCs) within the 'T cell major' population across individual samples from 'Adj_normal' (adjacent normal tissue) and 'Tumor' conditions. Each bar represents a distinct sample, with segments indicating the proportional contribution of each cell subtype within that sample's T cell compartment. The goal is to identify shifts in the immune cell composition between healthy and cancerous colon tissues.

Visual Summary

The visualization clearly distinguishes between the cellular compositions of 'Adj_normal' and 'Tumor' samples.

• Dominant T cell subsets: In both 'Adj_normal' and 'Tumor' conditions, 'T cell (Cytotoxic)' and 'T cell (Naive)' constitute a significant proportion of the T cell compartment.
• Treg enrichment in Tumor: A striking difference is the apparent expansion of 'T cell (Treg)' (dark blue segment) in the 'Tumor' condition. These cells occupy a noticeably larger proportion of the T cell population across most tumor samples compared to adjacent normal samples, where their presence is minimal.
• Relative reduction of Cytotoxic T cells: While 'T cell (Cytotoxic)' remains a major component in tumor samples, its *relative proportion* appears to be lower in many tumor samples compared to adjacent normal samples, particularly when considering the expansion of Tregs.
• Other T cell subsets and ILCs: T helper subsets like 'T cell (Th1)', 'T cell (Th17)', 'T cell (Th2)', 'T cell (Th9)', 'T cell (Th22)', and 'T cell (Tfh)' are present in relatively smaller proportions in both conditions, though their relative contribution might slightly differ between samples. NK cells and various ILC subtypes (ILC1, ILC2, ILC3 (NCR+), ILC3 (NCR-), ILCreg, LTI) are present in very low proportions across most samples in both conditions.
• Inter-sample variability: There appears to be higher heterogeneity in the cellular composition among tumor samples compared to the more consistent profiles observed in adjacent normal samples.

Biological Interpretation

The observed shifts in T cell subset populations provide critical insights into the immune microenvironment in colorectal cancer (CRC).

• Treg Expansion: The marked increase in 'T cell (Treg)' proportion within the tumor microenvironment is a well-established hallmark of immune evasion in many cancers, including CRC [1]. Tregs are potent immunosuppressive cells that inhibit effector T cell functions, dampen anti-tumor immunity, and promote tumor growth and metastasis. Their elevated presence suggests an active mechanism of immune suppression within the colorectal tumors.
• Implications for Cytotoxic T cells: While 'T cell (Cytotoxic)' cells are crucial for directly killing cancer cells, their *relative reduction* (or lack of substantial increase) in the context of increased Tregs within the tumor suggests an unfavorable immune balance. This could imply either a decreased infiltration of cytotoxic T cells, their exhaustion, or active suppression by the expanded Treg population, thereby hindering effective anti-tumor responses.
• Naive T cells: The presence of 'T cell (Naive)' cells, while expected, may suggest ongoing T cell recruitment or less extensive differentiation of T cells within the tumor compared to adjacent normal tissue. However, a relative decrease in naive cells in the tumor could also reflect their differentiation into effector or regulatory phenotypes.
• Overall Immune Context: The data points towards an immunosuppressive tumor microenvironment in CRC, characterized by an increased Treg presence, which could contribute to tumor progression by hindering the anti-tumor activity of cytotoxic T cells.

Clinical or Translational Implications

These findings have significant clinical and translational implications for colorectal cancer:

• Prognostic Marker: An elevated proportion of Tregs in the tumor microenvironment is often associated with poor prognosis and reduced survival in CRC patients [2]. This analysis reinforces the potential utility of Treg quantification as a prognostic biomarker.
• Immunotherapy Resistance: The dominance of immunosuppressive Tregs could explain resistance to certain immunotherapies that aim to activate effector T cells. Strategies targeting Tregs, such as depletion or inhibition of their function (e.g., via anti-CTLA-4 antibodies or other novel approaches), could be beneficial to enhance anti-tumor immunity [3].
• Therapeutic Targets: Understanding the specific T cell subset imbalances provides a rationale for developing targeted therapies. For instance, combination therapies that simultaneously inhibit Tregs and activate cytotoxic T cells might prove more effective in CRC.
• Monitoring Treatment Response: Changes in the proportions of these T cell subsets could serve as valuable biomarkers to monitor patient response to treatment and predict therapeutic efficacy.

---

References:

[1] Ohue, Y., & Nishikawa, H. (2019). Regulatory T Cells in Cancer: From Tumor Promotion to Tumor Suppression. *Immunity*, 50(2), 266–279. PubMed Search: Regulatory T Cells Cancer Immunity

[2] Shang, B., Liu, Y., Jiang, S. J., & Guo, R. (2015). Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in patients with colorectal cancer: A systematic review and meta-analysis. *Oncotarget*, 6(32), 33762–33771. PubMed Search: FoxP3+ regulatory T cells colorectal cancer prognosis

[3] Knochelmann, H. M., Dwyer, C. J., Smith, A. R., Patton, J. T., Kassim, S. H., & Sannasgala, N. M. (2018). The Role of CTLA-4 in Cancer Immunotherapy. *Frontiers in Oncology*, 8, 386. GeneCards: CTLA4

8. Differential Abundance of T cell Subsets in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional differences of various T cell subsets between Tumor and adjacent normal (Adj_normal) colon tissue samples. Box plots are used to visualize the cell type proportions, and statistical significance is assessed to identify subsets with notable changes in the colorectal cancer microenvironment. The analysis focuses on T cell populations, which are critical components of the adaptive immune system and play diverse roles in cancer progression and response.

Visual Summary

The box plots illustrate the distribution of cell type proportions for eight T cell subsets across 'Tumor' and 'Adj_normal' conditions, with statistically significant differences indicated by p-values.

• Treg (Regulatory T cells): Displayed a highly significant increase in proportion within 'Tumor' samples (median approximately 14-15%) compared to 'Adj_normal' samples (median approximately 3-4%) (p=4.63e-09).
• Th17 (T helper 17 cells): Showed a significantly higher proportion in 'Tumor' samples (median approximately 7%) than in 'Adj_normal' samples (median approximately 4%) (p=0.00115).
• ILC1 (Group 1 Innate Lymphoid Cells): Exhibited a highly significant decrease in 'Tumor' samples (median approximately 0.5%) compared to 'Adj_normal' samples (median approximately 2.8%) (p=1.12e-05).
• LTI (Lymphoid Tissue Inducer cells): Presented a significant reduction in 'Tumor' samples (median approximately 2%) compared to 'Adj_normal' samples (median approximately 6%) (p=0.000133).
• ILC2 (Group 2 Innate Lymphoid Cells): Showed a significant decrease in 'Tumor' samples (median approximately 0.1%) compared to 'Adj_normal' samples (median approximately 0.3%) (p=0.0386).
• Th9 (T helper 9 cells): Indicated a marginally significant decrease in 'Tumor' samples (median approximately 0.25%) compared to 'Adj_normal' samples (median approximately 0.2%) (p=0.0541).
• T_Cyto (Cytotoxic T cells): Displayed a marginally significant decrease in 'Tumor' samples (median approximately 40%) compared to 'Adj_normal' samples (median approximately 50%) (p=0.0676).
• Tfh (T follicular helper cells): Showed a marginally significant increase in 'Tumor' samples (median approximately 13%) compared to 'Adj_normal' samples (median approximately 10%) (p=0.0813).

Biological Interpretation

The observed shifts in T cell subset proportions within the colorectal tumor microenvironment provide critical insights into the immune landscape associated with colorectal cancer progression.

Immune Evasion and Suppression:

• The striking increase in Treg cell proportion in tumors is a classic hallmark of immune evasion in many cancers, including colorectal cancer. Tregs suppress effector T cell responses, thereby limiting anti-tumor immunity and allowing cancer cells to escape immune surveillance [1].
• The marginally significant decrease in Cytotoxic T cells (T_Cyto) in the tumor further supports a dampened anti-tumor immune response. CD8+ T_Cyto cells are crucial for directly killing cancer cells, and their reduced presence suggests a compromised ability of the immune system to clear the tumor [2].

Altered Innate Lymphoid Cell Landscape:

• The significant reduction in ILC1 and ILC2 populations within the tumor microenvironment suggests a broad dysregulation of innate immune responses. ILC1s are known to produce IFN-$\gamma$ and contribute to anti-tumor immunity, while ILC2s mediate type 2 immunity, often associated with tissue repair but sometimes with pro-tumorigenic effects depending on the context [3]. Their general decline points to an altered innate immune balance.
• LTI cells, which are crucial for lymphoid tissue development, are also significantly reduced in tumors. This might reflect an impairment in the formation of organized immune structures, such as tertiary lymphoid structures, which can be critical for effective anti-tumor immunity [4].

Context-Dependent T helper Responses:

• The significant increase in Th17 cells in tumors is notable. Th17 cells have a context-dependent role in cancer; they can be pro-tumorigenic by promoting inflammation, angiogenesis, and recruiting immunosuppressive cells, or anti-tumorigenic by enhancing anti-tumor responses [5]. In CRC, a pro-tumorigenic role is often suggested due to their association with chronic inflammation.
• The marginally significant increase in Tfh cells in tumors could suggest an activated B cell response, as Tfh cells are essential for B cell maturation and antibody production. The precise implication in CRC requires further investigation, as B cell responses can be both protective and detrimental in cancer [6].
• The marginally significant decrease in Th9 cells might indicate an alteration in specific cytokine milieus. Th9 cells produce IL-9, which has been implicated in both anti-tumor immunity and tumor promotion, depending on the tumor type and microenvironment [7].

Clinical or Translational Implications

These findings have several potential clinical and translational implications for colorectal cancer:

• Biomarkers for Prognosis and Response: The relative proportions of Treg, Th17, ILC1, ILC2, and T_Cyto cells could serve as prognostic biomarkers in CRC. For instance, a high Treg/T_Cyto ratio is often associated with poor prognosis and resistance to immunotherapy.

Immunotherapeutic Targets:

• The expansion of Tregs in the tumor microenvironment highlights them as a potential therapeutic target. Strategies aimed at depleting Tregs or inhibiting their suppressive function could enhance anti-tumor immunity [1].
• The decrease in T_Cyto cells underscores the need for therapies that promote their infiltration, activation, and persistence within the tumor, such as immune checkpoint inhibitors or adoptive T cell therapies [2].

• Understanding Immune Evasion Mechanisms: The comprehensive analysis of these T cell subsets provides a deeper understanding of how the immune system is dysregulated in colorectal cancer, leading to immune evasion. This knowledge can inform the development of novel immunotherapeutic strategies designed to reverse this immunosuppressive environment.
• Patient Stratification: These immune signatures could potentially be used to stratify patients for different treatment approaches. For example, patients with a highly immunosuppressive TME (e.g., high Tregs, low T_Cyto) might benefit more from combination therapies that counteract immune suppression.

---

References:

[1] Ohue, Y., & Nishikawa, H. (2019). Regulatory T cells in cancer: from tumor promotion to tumor suppression. *Cancer Science*, 110(5), 1888-1894. PubMed Search: "regulatory T cells cancer immunosuppression"

[2] Chen, D. S., & Mellman, I. (2017). Elements of cancer immunity and the cancer-immune set point. *Nature*, 541(7637), 321-330. PubMed Search: "cytotoxic T cells anti-tumor immunity"

[3] Vivier, E., Artis, D., Colonna, A., Diefenbach, A., Di Santo, J. P., Eberl, G., ... & Zucchelli, M. (2018). Innate Lymphoid Cells: 10 Years On. *Cell*, 174(5), 1054-1066. PubMed Search: "ILC1 ILC2 cancer role"

[4] Panteleev, M. A., & Gelfand, M. S. (2020). Lymphoid tissue inducer cells in cancer: from fundamental insights to therapeutic strategies. *Frontiers in Immunology*, 11, 2191. PubMed Search: "lymphoid tissue inducer cells cancer"

[5] Gaffen, S. L., & Hernandez, S. (2021). Th17 cell biology in disease: From inflammatory bowel disease to colorectal cancer. *Frontiers in Immunology*, 12, 638634. PubMed Search: "Th17 cells colorectal cancer"

[6] Vinuesa, C. G., Linterman, M. A., Goodnow, C. C., & Randall, K. L. (2009). T follicular helper cells from naive precursors in vivo. *Nature Reviews Immunology*, 9(7), 441-447. GeneCards: TFH

[7] Lu, Y., & Chen, Y. H. (2019). The plasticity of Th9 cells in cancer. *Frontiers in Immunology*, 10, 1515. PubMed Search: "Th9 cells cancer IL-9"

9. Macrophage Subset Population Analysis in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot showing the relative proportions of various macrophage subsets (Macrophage M1, M2A, M2B, M2C, M2D) across individual samples from both 'Adj_normal' (adjacent normal colon tissue) and 'Tumor' (colorectal tumor tissue) conditions. The data is derived from single-cell RNA sequencing, providing insights into the cellular composition of the tumor microenvironment with respect to macrophage polarization states.

Visual Summary

The stacked bar plots illustrate distinct differences in macrophage subset distributions between adjacent normal and tumor tissues.

Adj_normal Samples:

• The 'Adj_normal' samples exhibit a more heterogeneous distribution of macrophage subsets.
• Macrophage (M2D) (teal) is notably abundant in some adjacent normal samples (e.g., SMC03-N), sometimes comprising nearly 100% of macrophages.
• Macrophage (M2A) (orange) is also prominent, particularly in samples like SMC07-N, SMC09-N, and SMC05-N, often making up a substantial portion of the M2-like macrophages.
• Macrophage (M1) (burgundy) is present in varying proportions, increasing in some samples towards the right side of the 'Adj_normal' panel (e.g., SMC08-N, SMC05-N), sometimes reaching over 40% of the total macrophages.
• Macrophage (M2B) (light yellow) and (M2C) (light green) are generally minor components in most adjacent normal samples, though present.

Tumor Samples:

• The 'Tumor' samples show a consistent and pronounced shift in macrophage composition compared to 'Adj_normal'.
• Macrophage (M1) (burgundy) generally appears to be enriched in tumor samples, often constituting a larger proportion than in many adjacent normal samples. In several tumor samples (e.g., SMC06-T, SMC01-T, SMC23-T, SMC25-T, SMC11-T), M1 macrophages account for approximately 30-50% of the total macrophage population.
• Macrophage (M2B) (light yellow) is consistently and highly abundant across almost all tumor samples, often comprising the largest single fraction of macrophages, frequently exceeding 40-50% and sometimes reaching up to 70% of the total macrophage population.
• Macrophage (M2A) (orange), (M2C) (light green), and (M2D) (teal) subsets are generally present in smaller proportions in tumor samples compared to M1 and M2B, and their contribution is often less pronounced than in some 'Adj_normal' samples. M2A contributes some fraction (e.g., ~10-20%), while M2C and M2D are consistently low.
• Overall, tumor samples exhibit a dominant presence of M1 and M2B macrophages, with M2B often being the single largest subset.

Biological Interpretation

The observed shifts in macrophage populations provide critical insights into the immune microenvironment in colorectal cancer. Macrophages are highly plastic cells that can adopt diverse functional states, broadly categorized into pro-inflammatory M1-like and immunomodulatory/pro-tumorigenic M2-like phenotypes.

• Shift in Macrophage Polarization: The most striking observation is the significant and consistent enrichment of Macrophage (M2B) in the tumor microenvironment compared to adjacent normal tissue. M2B macrophages are a less commonly studied subset of M2 macrophages, but they are generally associated with immune regulation and have been implicated in tumor progression and angiogenesis in some contexts. Their dominance suggests a strong pro-tumorigenic or immunosuppressive environment.
  • The concurrent increase in Macrophage (M1) in tumor samples is also notable. M1 macrophages are typically characterized by their ability to produce pro-inflammatory cytokines, present antigens, and directly kill tumor cells, often associated with anti-tumor immunity. However, their presence alongside a strong M2B signal suggests a complex, potentially mixed, or dynamically shifting immune landscape within the tumor. It could also indicate an ongoing but perhaps ineffective anti-tumor immune response or M1-like macrophages being reprogrammed within the TME.
• Context of Colorectal Cancer: In colorectal cancer, the tumor microenvironment (TME) is known to be heavily infiltrated by various immune cells, including macrophages. Tumor-associated macrophages (TAMs) are typically polarized towards an M2-like phenotype, which promotes tumor growth, metastasis, angiogenesis, and immunosuppression. The prominent presence of M2B macrophages strongly aligns with this established role of TAMs in supporting cancer progression. The inferred tumor-origin cell type being 'Intestinal Epithelial cell' further grounds these observations in the context of epithelial-derived colorectal carcinoma.
• Heterogeneity within Conditions: The variability observed within 'Adj_normal' samples, particularly the high prevalence of M2D in some and M2A/M1 in others, suggests that even normal adjacent tissue can have diverse immune compositions, possibly reflecting individual differences, micro-environmental variations, or early pre-cancerous changes. However, the 'Tumor' samples show a more consistent pattern of M1 and M2B dominance, suggesting a tumor-driven reprogramming of the macrophage compartment.

Clinical or Translational Implications

The distinct macrophage population profiles observed in colorectal tumor tissue compared to adjacent normal tissue have several potential clinical and translational implications:

• Biomarker Potential: The increased proportions of Macrophage (M1) and especially Macrophage (M2B) could serve as potential diagnostic or prognostic biomarkers for colorectal cancer. Ratios or absolute numbers of these subsets might correlate with disease stage, treatment response, or patient outcomes.
• Therapeutic Targeting: The strong presence of M2B macrophages in tumors highlights them as a potential therapeutic target. Strategies aimed at inhibiting M2B macrophage function, depleting them, or repolarizing them towards a more M1-like, anti-tumor phenotype could be explored to enhance anti-cancer immunity.
  • For example, therapies designed to modulate macrophage polarization (e.g., using CSF1R inhibitors, or agents that promote M1 polarization) might be particularly relevant in colorectal cancer patients exhibiting a high M2B burden.
• Immunotherapy Response Prediction: The specific macrophage polarization landscape could potentially influence the efficacy of existing immunotherapies. Patients with a highly M2B-dominant TME might be less responsive to certain checkpoint inhibitors, suggesting a need for combination therapies that address macrophage-mediated immunosuppression.
• Research Focus: Further research into the specific functional roles of M2B macrophages in colorectal cancer is warranted, including their interactions with other immune cells and their contribution to various aspects of tumor progression (e.g., angiogenesis, metastasis, immune evasion).

10. Differential Macrophage Subset Proportions in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional changes of distinct macrophage subsets (M1, M2A, M2B) between 'Adj_normal' (adjacent normal) and 'Tumor' conditions within human colon tissue, as derived from single-cell RNA-seq data. The goal is to identify statistically significant shifts in these immune cell populations, which are critical components of the tumor microenvironment in colorectal cancer. The analysis uses box plots to visualize cell type proportions and statistical tests to determine significance (p-value cutoff: 0.1).

Visual Summary

The box plots illustrate the distribution of celltype proportions for three macrophage subsets: Mac (M2A), Mac (M2B), and Mac (M1), comparing 'Adj_normal' and 'Tumor' conditions.

• Mac (M2A): There is a highly statistically significant decrease in the proportion of Mac (M2A) cells in the 'Tumor' condition compared to the 'Adj_normal' condition (p = 0.00222). The median proportion drops substantially from approximately 30% in 'Adj_normal' to around 5-10% in 'Tumor'.
• Mac (M2B): Conversely, Mac (M2B) cells show a highly statistically significant increase in proportion in the 'Tumor' condition (p = 0.00229). The median proportion rises from approximately 10-15% in 'Adj_normal' to about 35-40% in 'Tumor'.
• Mac (M1): The proportion of Mac (M1) cells appears slightly higher in the 'Tumor' condition, but this difference is only borderline statistically significant (p = 0.0896), falling just below the 0.1 cutoff. The median proportions are relatively similar, around 30-35% in 'Adj_normal' and 35-40% in 'Tumor'.

Biological Interpretation

Macrophages are highly plastic immune cells that polarize into different functional states, primarily M1 (pro-inflammatory, anti-tumor) and M2 (anti-inflammatory, pro-tumor), with various M2 subtypes (M2A, M2B, M2C, M2D) existing within the tumor microenvironment. The observed shifts in macrophage subsets between adjacent normal colon tissue and colorectal tumor tissue provide key insights into the immune landscape of colorectal cancer.

• Decreased M2A Macrophages in Tumor: M2A macrophages are typically associated with allergic responses and tissue repair, often considered to contribute to immune suppression and tumor progression in many contexts. The observed significant *decrease* in M2A cells in the tumor environment is notable and suggests a potential shift away from this specific M2 subtype or a different role in the context of colorectal cancer compared to other M2 subtypes. This could imply that M2A is less critical for the tumor-promoting environment in this specific dataset, or that other M2 subtypes become more dominant.
• Increased M2B Macrophages in Tumor: The significant *increase* in M2B macrophages within the tumor is a strong indicator of their involvement in colorectal cancer progression. M2B macrophages are known to be induced by immune complexes and Toll-like receptor (TLR) agonists and have a complex phenotype, producing both pro-inflammatory (e.g., IL-1β, TNF-α) and anti-inflammatory (e.g., IL-10) cytokines. In the tumor microenvironment, an increase in M2B-like macrophages can contribute to immune evasion, angiogenesis, and tumor growth by creating an immunosuppressive milieu, promoting tissue remodeling, and fostering chronic inflammation that benefits tumor cells [PubMed search: M2B macrophages cancer].
• M1 Macrophages: While M1 macrophages are generally considered anti-tumorigenic due to their ability to present antigens and produce cytotoxic mediators, their slight, borderline-significant increase in the tumor setting is less conclusive. This could suggest that while some M1 polarization may occur, it might be insufficient to overcome the pro-tumorigenic effects driven by other immune cells, particularly the increased M2B population. The tumor microenvironment is often characterized by factors that skew macrophage polarization towards M2 phenotypes, even in the presence of M1-inducing signals.

Overall, the findings highlight a clear reprogramming of the macrophage compartment in colorectal cancer, with a significant shift away from M2A and towards M2B phenotypes. This emphasizes the complex and context-dependent nature of macrophage polarization in cancer.

Clinical or Translational Implications

The significant alteration in macrophage subset proportions, particularly the robust increase in M2B macrophages in colorectal tumor tissue, suggests potential clinical and translational implications:

• Biomarker Potential: The proportion of M2B macrophages could serve as a prognostic biomarker for colorectal cancer. Higher levels of M2B macrophages in tumors might correlate with disease progression, metastasis, or resistance to therapy, warranting further investigation.
• Therapeutic Targeting: The distinct enrichment of M2B macrophages in the tumor microenvironment positions them as potential therapeutic targets. Strategies aimed at repolarizing M2B macrophages towards an M1-like anti-tumor phenotype, or depleting them, could be explored as novel immunotherapeutic approaches for colorectal cancer [PubMed search: macrophage reprogramming cancer therapy]. Modulating the signals that promote M2B polarization could disrupt key mechanisms of tumor progression.
• Understanding Tumor Immunity: These findings contribute to a deeper understanding of the specific macrophage subsets that drive tumor immunity or immune evasion in colorectal cancer. Such insights are crucial for developing more effective, precision immunotherapies tailored to the specific immune landscape of the patient's tumor.

11. Ploidy Analysis of Intestinal Epithelial Cells in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the ploidy status (Aneuploid, Diploid, or Unclear) within Intestinal Epithelial cells, identified as the tumor-origin cell type, across individual samples from both 'Adj_normal' (adjacent normal) and 'Tumor' conditions. The results are presented as stacked bar plots, with each bar representing a sample and showing the proportion of cells belonging to each ploidy category.

Visual Summary

The visualization clearly distinguishes the ploidy landscapes between adjacent normal and tumor intestinal epithelial cells:

• Adjacent Normal Samples (Adj_normal): All analyzed adjacent normal samples (e.g., SMC01-N, SMC02-N) consist almost exclusively of diploid Intestinal Epithelial cells. There is a near-complete absence of aneuploid cells in these samples.
• Tumor Samples (Tumor): In stark contrast, tumor samples display a highly variable and generally elevated proportion of aneuploid Intestinal Epithelial cells.
  • Some tumor samples (e.g., SMC23-T, SMC19-T, SMC10-T) show a mixed population, with a notable proportion of diploid cells still present (ranging from approximately 60% to 75% diploid).
  • Other tumor samples (e.g., SMC06-T, SMC14-T, SMC07-T, SMC25-T, SMC04-T, SMC08-T, SMC22-T, SMC11-T, SMC15-T, SMC01-T, SMC18-T, SMC02-T, SMC20-T, SMC09-T, SMC16-T, SMC21-T) are predominantly composed of aneuploid cells, with the aneuploid proportion exceeding 80-90% in many cases.
  • The 'Unclear' ploidy category constitutes a minor fraction across most samples, appearing slightly more often in some tumor samples but remaining a small overall percentage.

Biological Interpretation

The observed ploidy patterns are highly consistent with the known biology of colorectal cancer and reinforce the identification of Intestinal Epithelial cells as the malignant population.

1. Genomic Stability in Normal Tissue: The overwhelming diploid status of Intestinal Epithelial cells in adjacent normal tissue reflects the genomic stability of healthy somatic cells. This serves as an important baseline, confirming that aneuploidy is not a general characteristic of colon epithelial cells but rather a pathological feature.
2. Aneuploidy as a Hallmark of Cancer: The significant and widespread presence of aneuploidy in Intestinal Epithelial cells from tumor samples is a strong indicator of genomic instability, a well-recognized hallmark of cancer development and progression. Aneuploidy, or an abnormal number of chromosomes, is often associated with dysregulated cell division and contributes to oncogenesis by altering gene dosage and promoting further genomic alterations [PubMed search: "aneuploidy cancer hallmark"].
3. Tumor Heterogeneity: The variability in the proportion of aneuploid cells across different tumor samples (e.g., some tumors are only ~30% aneuploid, while others are >90%) highlights inter-tumor heterogeneity. This suggests that tumors may be at different stages of progression or have adopted distinct evolutionary paths regarding genomic instability. It could also reflect varying proportions of non-malignant epithelial cells mixed within the tumor sample.
4. Confirmation of Tumor Origin: Given that Intestinal Epithelial cells were resolved as the "tumor-origin cell type," the robust increase in aneuploidy specifically within this cell type in tumor samples strongly supports their malignant transformation and proliferation within the tumor microenvironment.

Clinical or Translational Implications

These findings have several important clinical and translational implications in the context of colorectal cancer:

• Diagnostic and Prognostic Biomarker: The high prevalence of aneuploidy in tumor-derived Intestinal Epithelial cells, particularly when compared to adjacent normal tissue, underscores its potential as a diagnostic marker for colorectal cancer. The degree of aneuploidy might also hold prognostic value, with higher aneuploidy potentially correlating with more aggressive disease or advanced stages, although this would require further clinical correlation.
• Therapeutic Targeting: Genomic instability and aneuploidy often create vulnerabilities that can be exploited therapeutically. For instance, some cancer therapies specifically target pathways involved in DNA repair or cell cycle checkpoints, which are frequently compromised in aneuploid cells [GeneCards: "Aneuploidy and therapeutic targets"]. The observed heterogeneity in aneuploidy across patients might suggest that personalized approaches based on a tumor's genomic instability profile could be beneficial.
• Monitoring Tumor Evolution: Tracking aneuploidy patterns in Intestinal Epithelial cells could be valuable for monitoring disease progression, recurrence, or response to treatment, providing insights into the evolving genomic landscape of the tumor.

12. Cell-Cell Interaction Analysis in Colorectal Cancer: Contrasting Tumor and Adjacent Normal Microenvironments

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction (CCI) patterns using CellPhoneDB, focusing on key cell types involved in the colorectal cancer microenvironment: Intestinal Epithelial cells, Fibroblasts, Macrophages, CD4+ T cells, and CD8+ T cells. The interactions are compared between "Adj_normal" (adjacent normal tissue) and "Tumor" conditions to highlight context-specific communication changes. The dot plots visualize the significance of interactions (dot size, -log10(p-value)) and the strength of interaction (dot color, log2(mean expression)). This provides insights into the intricate signaling networks that characterize normal colon tissue versus the tumor microenvironment, with a particular emphasis on potential therapeutic targets and experimental validation strategies.

Visual Summary

The provided dot plots illustrate distinct cell-cell interaction landscapes in "Adj_normal" and "Tumor" conditions. Each plot displays interactions between specific cell type pairs (rows) and ligand-receptor complexes (columns), with dot size proportional to the statistical significance (higher -log10(p) means smaller p-value) and color intensity representing the mean expression level of the interacting partners (higher log2(m) means stronger interaction).

Adj_normal Condition

• Dominant Cell Types: Interactions prominently involve Diploid Intestinal Epi cells, which exhibit robust self-interactions and interactions with Fibroblast and various T cell subsets (T CD4+, T CD8+).
• Key Interaction Pairs: Significant interactions include various Collagen/integrin complexes (e.g., COL1A1_integrin_a1b1_complex, COL6A3_integrin_a1b1_complex), CDH1_integrin_aE_b7_complex, and FN1_integrin_a4b7_complex. These are crucial for cell adhesion, extracellular matrix (ECM) organization, and epithelial-stromal interactions in a healthy tissue context.
• Immune Surveillance: T cells show interactions with epithelial cells and fibroblasts, suggesting basal immune surveillance and homeostatic communication. ICAM3_integrin_aL_b2_complex is noted, important for leukocyte adhesion.

Tumor Condition

• Shift in Epithelial Identity: A striking difference is the emergence of Aneuploid Intestinal Epi cells, replacing the Diploid Intestinal Epi as the primary epithelial component. These aneuploid cells engage in a high number of significant interactions.
• Increased Macrophage Involvement: Macrophage (Mac) interactions are notably more pronounced in the tumor context, forming significant connections with Aneuploid Intestinal Epi and T cells.
• Altered Interaction Repertoire: The set of active ligand-receptor pairs is largely distinct from the normal condition, indicating a fundamental rewiring of intercellular communication.
• Prominent Tumor-Associated Interactions: Key interactions observed include APOE_TREM2 (Mac-Aneuploid Epi), CD86_CTLA4 (T cell-T cell, or T cell-Mac), EFNB2_EPHA4 (Aneuploid Epi self-interaction or with other cells), IL10_IL10RA_IL10RB (Mac-T cell), LGALS9_CD44 (T cell-Aneuploid Epi/Mac), PLAUR_LRP1, TGFB1_TGFBR1, and VEGF_VEGFR1/2. These are often implicated in immune suppression, tumor progression, and angiogenesis.
• Reduced Homeostatic Interactions: Some of the strong Collagen/integrin interactions observed in the normal state appear diminished or altered, reflecting ECM remodeling in cancer.

Biological Interpretation

The contrasting CCI patterns between adjacent normal colon tissue and colorectal tumor strongly reflect the dynamic and pathological alterations of the tumor microenvironment (TME).

Normal Tissue Homeostasis

In the adjacent normal tissue, the observed interactions largely represent mechanisms for maintaining tissue integrity and immune surveillance.

• Epithelial-Stromal Anchorage and Communication: Ligand-receptor pairs like CDH1_integrin_aE_b7_complex, various Collagen/integrin complexes, and FN1_integrin_a4b7_complex highlight strong epithelial-stromal connections crucial for maintaining gut barrier function and tissue architecture. E-cadherin (CDH1) mediated adhesion is vital for epithelial integrity [PubMed search: E-cadherin intestinal epithelial function]. Integrin interactions with collagen and fibronectin (e.g., FN1) facilitate cell-ECM interactions, influencing cell survival, proliferation, and differentiation [GeneCards: ITGA4, ITGB7].
• Basal Immune Regulation: Interactions involving T cells (e.g., ICAM3_integrin_aL_b2_complex) suggest ongoing immune surveillance, where lymphocytes interact with epithelial and stromal cells. TGFB1-TGFBR1 signaling, active in normal tissue, plays roles in tissue repair, differentiation, and immune tolerance [GeneCards: TGFB1].

Tumor Microenvironment Remodeling

The tumor microenvironment exhibits a profound shift in cellular communication, driven by the presence of Aneuploid Intestinal Epi cells and an altered immune and stromal landscape.

• Oncogenic Epithelial-Driven Interactions: The Aneuploid Intestinal Epi cells become central to the CCI network. Their interactions likely promote tumor growth, invasion, and immune evasion. For instance, increased EFNB2_EPHA4 interactions, potentially among tumor cells or with endothelial cells, can contribute to tumor growth, angiogenesis, and metastasis [GeneCards: EFNB2, EPHA4].
• Macrophage Reprogramming (TAMs): The heightened involvement of Macrophage cells, often indicative of tumor-associated macrophages (TAMs), points towards their pro-tumorigenic roles. The APOE_TREM2 interaction is notable between Macrophage and Aneuploid Intestinal Epi. TREM2 is expressed on TAMs and can promote tumor progression through various mechanisms, including enhancing phagocytosis of apoptotic tumor cells and modulating the immune response [PubMed search: TREM2 tumor associated macrophages]. The IL10_IL10RA_IL10RB axis, particularly between macrophages and T cells, is a potent immunosuppressive pathway, contributing to immune evasion in cancer [GeneCards: IL10].
• Immune Evasion and Suppression: Several interactions suggest mechanisms of immune evasion:
  • CD86_CTLA4: This immune checkpoint interaction, if primarily occurring on T cells or between T cells and antigen-presenting cells (like macrophages), signifies T-cell anergy or exhaustion [PubMed search: CTLA4 immune checkpoint].
  • LGALS9_CD44: Galectin-9 (LGALS9) can induce T-cell apoptosis and suppress anti-tumor immunity, often by interacting with CD44 on T cells or tumor cells [GeneCards: LGALS9].
• Angiogenesis and Extracellular Matrix Remodeling: The presence of VEGF_VEGFR1/2 interactions (potentially involving Aneuploid Intestinal Epi, Macrophage, and Endothelial cell which might be implicitly involved through ligand/receptor expression) is a hallmark of tumor angiogenesis, essential for tumor supply and growth [GeneCards: VEGFA]. PLAUR_LRP1 interactions are implicated in extracellular matrix degradation and cell migration, facilitating tumor invasion [GeneCards: PLAUR]. The TGFB1-TGFBR1 signaling also plays a pleiotropic role in the TME, promoting epithelial-mesenchymal transition (EMT), immunosuppression, and fibrosis [PubMed search: TGFB1 cancer EMT].

Clinical or Translational Implications

The identified cell-cell interaction changes in colorectal cancer offer several promising avenues for clinical and translational applications.

Therapeutic Target Prioritization:

• Immune Checkpoint Blockade and Reversal of Immunosuppression: Interactions like CD86_CTLA4, IL10_IL10RA_IL10RB, and LGALS9_CD44 represent potential targets for novel immunotherapies. Blocking these pathways could reactivate anti-tumor T-cell responses.
• Targeting TAM-Mediated Tumor Progression: The APOE_TREM2 axis on macrophages could be targeted to reprogram TAMs from pro-tumorigenic to anti-tumorigenic phenotypes, or to inhibit their recruitment and function [PubMed search: TREM2 inhibitor cancer].
• Inhibiting Angiogenesis and Metastasis: The enhanced VEGF_VEGFR1/2 and EFNB2_EPHA4 interactions highlight targets for anti-angiogenic therapies or agents that disrupt tumor cell migration and invasion. Existing drugs targeting VEGF are already used in CRC [PubMed search: VEGF inhibitors colorectal cancer].
• Modulating Stromal-Epithelial Crosstalk: The pervasive TGFB1_TGFBR1 signaling suggests TGFβ pathway inhibitors could be beneficial in reducing EMT, fibrosis, and immunosuppression within the TME [PubMed search: TGFB inhibitor cancer].

• Biomarker Discovery: Specific highly significant and tumor-enriched ligand-receptor pairs could serve as diagnostic or prognostic biomarkers. For instance, the expression levels of interacting partners in APOE-TREM2 or EFNB2-EPHA4 could be measured in patient samples to assess disease progression or response to therapy.
• Experimental Validation: The identified interactions provide a strong basis for further experimental validation.
  • In Vitro Co-culture Models: Specific cell type combinations (e.g., Aneuploid Intestinal Epi with Macrophage, or T cell with Aneuploid Intestinal Epi) can be co-cultured to functionally validate the identified ligand-receptor interactions using blocking antibodies or genetic knockdowns/overexpressions.
  • In Vivo Studies: Genetically engineered mouse models or patient-derived xenografts could be used to investigate the functional impact of targeting these CCI pathways on tumor growth, metastasis, and immune modulation.
  • Spatial Transcriptomics: Advanced spatial technologies could be employed to validate the proximity and co-expression of these ligand-receptor pairs in the human colon tumor microenvironment, confirming the spatial relevance of these interactions.

13. Condition-Specific Cell-Cell Interaction Patterns in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates condition-specific cell-cell interactions (CCIs) in human colon tissue, comparing 'Adj_normal' (adjacent normal) and 'Tumor' conditions using single-cell RNA-sequencing data. The dot plot visualizes the strength and significance of interactions between Intestinal Epithelial cells, major immune cells (B cell, Myeloid cell, T cell, Mast cell), and stromal cells (Fibroblast, Endothelial cell). Interaction strength is indicated by dot color (darker red = stronger), and statistical significance by dot size (larger dot = more significant -log10(p)). The analysis highlights CCIs that differ significantly between normal and tumor microenvironments.

Visual Summary

The dot plot effectively illustrates distinct cell-cell interaction landscapes in 'Adj_normal' versus 'Tumor' conditions.

• Condition-Specific Patterns: A clear segregation of prominent CCIs is observed. Interactions that are strong and highly significant in 'Adj_normal' samples are largely absent or weak in 'Tumor' samples, and vice versa. This indicates a profound remodeling of cellular communication in the tumor microenvironment.
  • The top-left quadrant (Adj_normal samples interacting via 'Adj_normal'-dominant CCIs) shows numerous large, dark red dots, signifying strong and significant interactions.
  • The bottom-right quadrant (Tumor samples interacting via 'Tumor'-dominant CCIs) also displays many large, dark red dots, indicating a distinct set of strong and significant interactions specific to the tumor context.
  • Conversely, the top-right and bottom-left quadrants show sparse, small, and lighter-colored dots, confirming the condition-specific nature of these interactions.

Key Interactions in 'Adj_normal' Condition:

• Many interactions involving ProstaglandinE2_byPTGES_PTGER4 are prominent, particularly between Fibroblasts (Fib | Fib) and Intestinal Epithelial cells (Ent.Epi | Fib). These show strong signal and significance across most normal samples.
• Several Collagen (COL14A1)-integrin_a1b1_complex interactions are also significant, primarily between Intestinal Epithelial cells (Ent.Epi) and Fibroblasts (Fib), suggesting a role in normal epithelial-stromal tissue integrity.
• TNFSF10_TNFRSF10B (TRAIL-TRAILR2) interactions, notably between T cell CD4+ and Endothelial cells (Endo), are consistently strong and significant in normal samples.
• CD320_JAML interactions between Intestinal Epithelial cells (Ent.Epi) and Endothelial cells (Endo) are also notable in the normal state.

Key Interactions in 'Tumor' Condition:

• A striking cluster of Collagen (COL1A1, COL2A1, COL3A1, COL4A1, COL4A2, COL5A1, COL5A2, COL6A3, COL12A1, COL15A1, COL18A1)-integrin_a1b1_complex interactions are highly enriched, especially between Fibroblasts (Fib) and Endothelial cells (Endo). These are among the strongest and most significant interactions in the tumor samples.
• VCAM1-integrin_a4b1_complex and VCAM1-integrin_a9b1_complex interactions are observed between Endothelial cells (Endo) and Fibroblasts (Fib), as well as various T cell subtypes (T cell CD4+, T cell CD8+), indicating roles in cell adhesion and migration.
• The VEGFA-FLT1 (VEGFR1) interaction, particularly between Endothelial cells (Endo) and Fibroblasts (Fib) or Intestinal Epithelial cells (Ent.Epi), is strongly activated in tumor samples.
• CXCL12-CXCR4 interactions between Fibroblasts (Fib) and T cell CD4+ or T cell CD8+ cells are prominent in the tumor setting.
• SPP1-integrin_a4b1_complex and SPP1-integrin_aVb1_complex interactions are strongly activated, primarily involving Fibroblasts (Fib).
• WNT2B-FZD1_LRP5 signaling interactions are notably present in tumor-associated Fibroblasts (Fib).

Biological Interpretation

The observed condition-specific CCI patterns underscore the dynamic changes in cellular communication that accompany colorectal cancer development and progression.

Interactions Enriched in 'Adj_normal' Conditions:

These interactions likely contribute to the maintenance of tissue homeostasis, immune surveillance, and normal physiological functions in the colon. The *loss* or *reduction* of these interactions in the tumor microenvironment can represent mechanisms of tumor evasion or altered tissue architecture.

ProstaglandinE2 by PTGES - PTGER4:

• Signaling Pathway/Mechanism: Prostaglandin E2 (PGE2), synthesized by PTGES, binds to its receptor PTGER4 (EP4). This GPCR-mediated signaling can modulate inflammation, immune responses, and epithelial proliferation. In normal tissue, appropriate PGE2 signaling is crucial for maintaining mucosal integrity and regulating immune cell activity.
• Biological Context: The strong presence of PGE2-PTGER4 signaling, especially between Fibroblasts and Intestinal Epithelial cells in the normal colon, may reflect baseline homeostatic or inflammatory regulatory processes. Its reduction in the tumor might indicate a shift in the inflammatory landscape or specific suppression of certain stromal-epithelial regulatory loops.
• GeneCards: PTGES | GeneCards: PTGER4

TNFSF10 (TRAIL) - TNFRSF10B (TRAILR2):

• Signaling Pathway/Mechanism: TRAIL (TNF-Related Apoptosis-Inducing Ligand) binding to its death receptor TNFRSF10B (also known as DR5) initiates the extrinsic apoptotic pathway, leading to programmed cell death. This is a critical mechanism for immune cells to eliminate unhealthy or transformed cells.
• Biological Context: Robust TRAIL-TRAILR2 signaling, particularly between T cells and Endothelial cells in normal tissue, suggests an active immune surveillance mechanism. The diminished presence of this interaction in tumor samples could indicate a strategy by cancer cells to evade immune-mediated apoptosis, potentially by downregulating TRAILR2 expression on tumor cells or disrupting TRAIL presentation by immune cells.
• GeneCards: TNFSF10 | GeneCards: TNFRSF10B

Interactions Enriched in 'Tumor' Conditions:

These interactions highlight crucial pro-tumorigenic mechanisms within the colorectal cancer microenvironment, often involving cancer-associated fibroblasts (CAFs), endothelial cells, and the tumor cells themselves (Intestinal Epithelial cells, particularly aneuploid ones).

Collagen (COLxxA1) - integrin_a1b1_complex:

• Signaling Pathway/Mechanism: Collagens are major components of the extracellular matrix (ECM). Their interactions with integrin receptors on cell surfaces mediate cell adhesion, migration, proliferation, and differentiation. The integrin_a1b1_complex (comprising ITGA1 and ITGB1) binds to various types of collagen.
• Biological Context: The widespread and strong activation of various collagen-integrin_a1b1_complex interactions, especially between Fibroblasts and Endothelial cells in tumor samples, indicates significant ECM remodeling and altered cell-matrix adhesion within the tumor microenvironment. This supports tumor cell invasion, metastasis, angiogenesis, and the survival of stromal cells crucial for tumor support.
• GeneCards: ITGA1 | GeneCards: ITGB1

VCAM1 - integrin_a4b1_complex and integrin_a9b1_complex:

• Signaling Pathway/Mechanism: VCAM1 (Vascular Cell Adhesion Molecule 1) is an adhesion molecule often upregulated on activated endothelial cells and some stromal cells. It binds to integrin receptors, notably integrin_a4b1 (comprising ITGA4 and ITGB1) and integrin_a9b1 (comprising ITGA9 and ITGB1). This interaction mediates cell-cell adhesion and cell migration, particularly for immune cells.
• Biological Context: Elevated VCAM1-integrin signaling in the tumor microenvironment, involving Endothelial cells, Fibroblasts, and T cells, can promote immune cell infiltration (which can be either anti-tumor or pro-tumor, depending on the immune cell phenotype) and may also facilitate tumor cell extravasation during metastasis.
• GeneCards: VCAM1 | GeneCards: ITGA4 | GeneCards: ITGA9

VEGFA - FLT1 (VEGFR1):

• Signaling Pathway/Mechanism: VEGFA (Vascular Endothelial Growth Factor A) is a potent angiogenic factor that binds to its receptor FLT1 (VEGFR1) on endothelial cells, initiating signaling cascades that promote endothelial cell proliferation, migration, and new blood vessel formation.
• Biological Context: The strong VEGFA-FLT1 interaction, especially between Endothelial cells and Fibroblasts or Intestinal Epithelial cells, is a hallmark of tumor angiogenesis in colorectal cancer. This process is essential for providing oxygen and nutrients to the rapidly growing tumor and for facilitating metastasis.
• GeneCards: VEGFA | GeneCards: FLT1

CXCL12 - CXCR4:

• Signaling Pathway/Mechanism: CXCL12 (Stromal Cell-Derived Factor 1) is a chemokine that binds to its receptor CXCR4. This axis is critical for cell migration, homing, and survival, activating downstream pathways like PI3K/Akt and MAPK.
• Biological Context: The prominent CXCL12-CXCR4 signaling between Fibroblasts and T cells in the tumor microenvironment plays a crucial role in shaping the immune landscape. It can promote the recruitment of immunosuppressive cells, facilitate tumor cell migration and metastasis, and enhance tumor cell survival and proliferation.
• GeneCards: CXCL12 | GeneCards: CXCR4

SPP1 (Osteopontin) - integrin_a4b1_complex and integrin_aVb1_complex:

• Signaling Pathway/Mechanism: SPP1 (Secreted Phosphoprotein 1 or Osteopontin) is a multifunctional cytokine that binds to various integrin receptors, including integrin_a4b1 (ITGA4-ITGB1) and integrin_aVb1 (ITGAV-ITGB1). SPP1 signaling promotes cell adhesion, migration, survival, and extracellular matrix remodeling.
• Biological Context: The strong SPP1-integrin interactions, primarily involving Fibroblasts, highlight SPP1's role in the tumor microenvironment of colorectal cancer. SPP1 is known to drive tumor progression, metastasis, angiogenesis, and immune evasion by modulating cell-matrix interactions and influencing immune cell functions.
• GeneCards: SPP1 | GeneCards: ITGAV

WNT2B - FZD1_LRP5 (Wnt/beta-catenin pathway):

• Signaling Pathway/Mechanism: WNT2B is a Wnt ligand that initiates canonical Wnt/beta-catenin signaling by binding to Frizzled (FZD1) and co-receptors like LRP5. This pathway regulates cell proliferation, differentiation, and stemness.
• Biological Context: Active WNT2B-FZD1_LRP5 signaling in tumor-associated Fibroblasts is highly relevant in colorectal cancer, where the Wnt pathway is frequently dysregulated. It can promote the proliferation and survival of both tumor cells and CAFs, contributing to tumor growth and progression, and potentially influencing the stemness characteristics of cancer cells.
• GeneCards: WNT2B | GeneCards: FZD1 | GeneCards: LRP5

Clinical or Translational Implications

The distinct cell-cell interaction profiles in colorectal cancer suggest several potential avenues for therapeutic intervention and biomarker development.

Targeting Tumor-Enriched Interactions:

• Integrin Signaling (COLxxA1-integrin, VCAM1-integrin, SPP1-integrin): Given the pervasive activation of integrin-mediated adhesion in the tumor microenvironment, particularly involving Fibroblasts and Endothelial cells, integrin inhibitors could be therapeutic targets. Inhibiting these interactions might disrupt ECM remodeling, reduce tumor cell invasion and metastasis, and suppress angiogenesis.
  • Therapeutic Agents: Several integrin inhibitors, though with varied success in clinical trials, have been developed (e.g., cilengitide targeting αvβ3/αvβ5 integrins, though not directly shown here, illustrates the concept). Further research on specific integrin complexes and their roles in CRC could lead to targeted therapies.
• VEGFA-FLT1 Axis: This pathway is a well-established target in cancer therapy. The strong signal confirms its importance in CRC angiogenesis.
  • Therapeutic Agents: Anti-VEGF antibodies (e.g., Bevacizumab) or VEGFR inhibitors (e.g., Ramucirumab) are standard treatments for metastatic colorectal cancer, aiming to starve the tumor of blood supply. The observed strong VEGFA-FLT1 interaction reinforces the rationale for these therapies.
• CXCL12-CXCR4 Axis: The activation of this chemokine axis suggests its role in tumor progression and immune evasion.
  • Therapeutic Agents: CXCR4 antagonists (e.g., Plerixafor, AMD3100) are being explored in clinical trials for various cancers to block metastasis, improve drug delivery, and enhance anti-tumor immune responses.
• Wnt Signaling (WNT2B-FZD1_LRP5): Dysregulation of the Wnt pathway is a known driver in CRC.
  • Therapeutic Agents: Wnt pathway inhibitors are an active area of drug development, with several compounds in preclinical and clinical stages aimed at blocking tumor cell proliferation and stemness.

Restoring or Enhancing Normal-Diminished Interactions:

• TNFSF10-TNFRSF10B (TRAIL-TRAILR2): The significant reduction of this pro-apoptotic signaling in tumor cells highlights a mechanism of immune evasion.
  • Therapeutic Agents: TRAIL receptor agonists (e.g., conatumumab, tigatuzumab) have been investigated to selectively induce apoptosis in cancer cells. Strategies to restore or enhance TRAIL-mediated killing could be explored, potentially in combination with other immunotherapies.

These findings provide mechanistic insights into colorectal cancer progression and offer potential strategies for developing novel therapies or optimizing existing ones by targeting critical cell-cell communication networks within the tumor microenvironment.

14. Condition-Specific Cell-Cell Interaction Patterns Involving Immune Checkpoint and Cell Cycle Pathways in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction (CCI) patterns involving genes associated with immune checkpoints and cell cycle pathways, specifically focusing on interactions between Intestinal Epithelial cells, major immune cells (e.g., T cells, Macrophages, Plasma cells), and stromal cells (e.g., Fibroblasts, Endothelial cells). The goal is to identify interactions that differ significantly between 'Adj_normal' and 'Tumor' conditions within human Colon tissue, providing insights into the colorectal cancer microenvironment. The analysis utilizes CellPhoneDB results and presents the findings as a dot plot, where dot size represents interaction significance (-log10(p-value)) and color intensity indicates scaled interaction strength.

Visual Summary

The dot plot effectively illustrates distinct cell-cell interaction landscapes between 'Adj_normal' and 'Tumor' conditions across multiple samples.

• Adj_normal Condition (Top-Left Quadrant): This section displays a high density of strong and significant interactions (large, dark red dots). Prominent interactions include ProstaglandinE2-PTGER4 signaling, various COL14A1-integrin interactions, and interactions involving TNFSF10-TNFRSF10D, DLL1-NOTCH2, and CD55-ADGRE5. These interactions predominantly involve Fibroblasts, Endothelial cells, Intestinal Epithelial cells, and T cells. The general pattern suggests active communication supporting tissue homeostasis, adhesion, and potentially immune surveillance in the normal adjacent tissue.
• Tumor Condition (Bottom-Right Quadrant): In contrast, the 'Tumor' condition exhibits a different, generally broader, and often more diffuse pattern of interactions. While some interactions remain strong, there's a clear emergence and upregulation of specific pathways. Key observations include:
  • Immune Checkpoint Interactions: Upregulated CD274 (PD-L1) - PDCD1 (PD-1) interactions are prominent, primarily between Macrophages and CD8+ T cells, and also between aneuploid Intestinal Epithelial cells and CD8+ T cells.
  • Growth Factor Signaling: A strong increase in interactions involving Epidermal Growth Factor Receptor (EGFR) ligands (AREG, HBEGF, EREG, TGFA, BTC) with EGFR. These interactions are observed across various cell types, including aneuploid Intestinal Epithelial cells, Fibroblasts, Endothelial cells, and Macrophages.
  • TGF-beta Signaling: Multiple interactions involving TGFB1, TGFB2, and TGFB3 with their respective receptors (TGFbeta_receptor1, TGFbeta_receptor2, TGFbeta_receptor3) are significantly increased. These involve aneuploid Intestinal Epithelial cells, Fibroblasts, Macrophages, and T cells.
  • Integrin Signaling Shift: While integrin interactions are present in both conditions, there's a shift in the specific types and strengths. In the Tumor, various collagen (COL1A1, COL11A1, COL12A1) interactions with integrin_a1b1_complex are prominent, particularly involving Fibroblasts, Endothelial cells, and Intestinal Epithelial cells.
  • Decreased Interactions: Several interactions strong in 'Adj_normal', particularly certain ProstaglandinE2-PTGER4 and COL14A1-integrin interactions, appear diminished or absent in the 'Tumor' condition, indicating a loss of normal communication patterns.

The blue boxes in the crop hints delineate clusters of interactions that are distinctly enriched in either the 'Adj_normal' (upper left) or 'Tumor' (lower right) conditions, highlighting the condition-specific nature of these CCI patterns.

Biological Interpretation

The observed shifts in cell-cell interactions between normal and tumor colon tissue provide critical insights into the pathophysiology of colorectal cancer. The analysis specifically highlights changes in pathways related to immune evasion, cell proliferation, and extracellular matrix remodeling, consistent with known cancer hallmarks.

1. Immune Evasion via Checkpoint Pathways:
   • The striking upregulation of the CD274 (PD-L1) - PDCD1 (PD-1) axis in the 'Tumor' microenvironment is a hallmark of immune evasion. PD-L1 on tumor cells (here, aneuploid Intestinal Epithelial cells) and tumor-associated immune cells (Macrophages) binds to PD-1 on T cells, suppressing anti-tumor immune responses. This allows cancer cells to escape destruction by the immune system [PubMed search for PD-1 PD-L1 colorectal cancer immunotherapy: PubMed Search].
2. Oncogenic Signaling Driving Proliferation and Survival:
   • The significant increase in interactions involving various Epidermal Growth Factor (EGF) family ligands (AREG, HBEGF, EREG, TGFA, BTC) and their receptor EGFR in the 'Tumor' condition is highly indicative of hyperactivated growth signaling. EGFR signaling is a potent driver of cell proliferation, survival, migration, and angiogenesis, all crucial for tumor growth. This is particularly relevant as 'Intestinal Epithelial cells' are identified as the tumor-origin cell type, and these cells show strong EGFR interactions, along with stromal and immune cells creating a pro-tumorigenic niche [PubMed search for EGFR colorectal cancer signaling: PubMed Search].
3. Tumor Microenvironment Remodeling and Immunosuppression:
   • TGF-beta (TGFB1/2/3) - TGFbeta_receptor1/2/3 interactions are highly active in the 'Tumor' context. TGF-beta is a pleiotropic cytokine that, in the context of cancer, often acts as a tumor promoter. It can induce epithelial-mesenchymal transition (EMT), promote angiogenesis, and profoundly suppress anti-tumor immunity by inhibiting T cell proliferation and function, and promoting the differentiation of regulatory T cells and myeloid-derived suppressor cells [PubMed search for TGF-beta colorectal cancer immune suppression: PubMed Search].
   • Altered integrin signaling (e.g., COL1A1, COL11A1, COL12A1 with integrin_a1b1_complex) reflects changes in the extracellular matrix (ECM) and cell adhesion. Cancer-associated fibroblasts (Fibroblasts in the plot) are key players in remodeling the ECM, which can impact tumor cell invasion, migration, and drug resistance.
4. Loss of Normal Homeostatic Interactions:
   • The decreased strength of ProstaglandinE2-PTGER4 interactions, particularly involving Fibroblasts and T cells in the 'Tumor' context, suggests a shift away from certain homeostatic or inflammatory-resolving pathways prevalent in normal tissue. While PGE2 can have complex roles, its altered pattern reflects a disrupted tissue microenvironment.

Clinical or Translational Implications

The identified differential cell-cell interactions represent crucial biological mechanisms in colorectal cancer progression and offer several potential clinical and translational implications:

1. Established Immunotherapy Targets:
   • The pronounced CD274 (PD-L1) - PDCD1 (PD-1) axis in the tumor microenvironment strongly supports the use of immune checkpoint inhibitors (e.g., anti-PD-1 or anti-PD-L1 antibodies) for colorectal cancer patients, particularly those with specific molecular features like microsatellite instability (MSI-H). This data provides direct evidence of this interaction in the context of specific cell types [PubMed search for PD-1 PD-L1 inhibitors colorectal cancer: PubMed Search].
2. Targeting Growth Factor Pathways:
   • The widespread upregulation of EGFR signaling by multiple ligands highlights EGFR as a critical therapeutic target. Anti-EGFR monoclonal antibodies (e.g., Cetuximab, Panitumumab) are standard treatments for RAS wild-type metastatic colorectal cancer. This analysis reinforces the importance of this pathway across multiple interacting cell types in the tumor [PubMed search for anti-EGFR therapy colorectal cancer: PubMed Search].
3. Emerging Targets for Microenvironment Modulation:
   • The significant increase in TGF-beta signaling indicates its potential as a therapeutic target to overcome immunosuppression and inhibit pro-tumorigenic stromal remodeling. TGF-beta pathway inhibitors are currently under investigation in clinical trials for various cancers, including CRC, aiming to restore anti-tumor immunity and reduce fibrosis [PubMed search for TGF-beta inhibitors cancer clinical trials: PubMed Search].
   • Modulation of specific integrin interactions could offer strategies to disrupt tumor cell invasion and metastasis or normalize the tumor vasculature. Research into integrin inhibitors for anti-cancer effects continues, particularly in combination therapies [PubMed search for integrin inhibitors cancer therapy: PubMed Search].
4. Diagnostic and Prognostic Biomarkers:
   • The differential expression of these CCI patterns between normal and tumor tissues suggests that specific ligand-receptor pairs or the overall interaction landscape could serve as novel diagnostic or prognostic biomarkers for colorectal cancer, potentially guiding patient stratification.

These findings underscore the complex interplay between tumor cells and the surrounding microenvironment and highlight several actionable targets for therapeutic intervention in colorectal cancer.

15. Intestinal Epithelial Cell Condition-Specific Surfaceome Markers in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers in Intestinal Epithelial cells, differentiating between Adj_normal, Diploid Tumor, and Tumor conditions within colorectal cancer samples. The goal is to highlight established and potential therapeutic targets based on their differential expression patterns in a dot plot visualization. The identification of surfaceome markers is critical as these proteins are accessible targets for antibody-based therapies or other cell-surface targeting strategies.

Visual Summary

The dot plot displays the expression of 60 surfaceome markers across various patient samples and conditions for Intestinal Epithelial cells. Each row represents a sample, categorized by condition (Adj_normal, Diploid SMCxx-T, SMCxx-T representing general 'Tumor' samples) and often patient ID. Each column represents a specific gene marker.

• Adj_normal Samples (top block): These samples show relatively high expression (darker red dots) and broad prevalence (larger dot size) for a distinct set of markers on the far left, such as PIGR, VSIG2, ITM2C, CDHR5. This pattern suggests these genes characterize the healthy or non-transformed intestinal epithelial state.
• Diploid Tumor Samples (middle block): These samples, derived from tumor tissue but identified as diploid, exhibit an intermediate expression profile. Many markers highly expressed in Adj_normal cells show reduced expression or prevalence, while markers highly expressed in the general Tumor samples start to show some upregulation, but generally less pronounced than in the 'Tumor' block.
• Tumor Samples (bottom block): This block, representing Intestinal Epithelial cells from tumor tissue (likely including aneuploid cells, which are 22.6% of the dataset and resolved as tumor-origin), shows a strikingly distinct expression pattern. A large cluster of markers on the right side of the plot exhibits very high mean expression (darkest red) and high fraction of cells expressing (largest dot sizes) across almost all tumor samples. This indicates a strong and consistent upregulation of these genes in the transformed malignant epithelial cells. Examples include CEACAM5, CEACAM6, EPCAM, CD44, ATP1A1, DDR1, EPHA2, MUC4, CD47, and PLAUR.

In summary, the plot clearly delineates three distinct molecular phenotypes corresponding to Adj_normal, Diploid Tumor, and the general Tumor condition, with the 'Tumor' group showing a prominent and consistent overexpression of numerous surfaceome markers. These highly upregulated markers in the 'Tumor' group are strong candidates for therapeutic targeting.

Biological Interpretation

The analysis identified numerous surfaceome markers differentially expressed in Intestinal Epithelial cells across different conditions. Focusing on the 'Tumor' condition, several markers show significant upregulation, making them relevant for colorectal cancer research and therapy. We distinguish between established therapeutic targets and less well-characterized markers with therapeutic potential.

Established Therapeutic Targets

These markers are well-documented in cancer biology and have existing therapeutic strategies or are under active clinical investigation.

1. CEACAM5 (Carcinoembryonic Antigen Related Cell Adhesion Molecule 5)
   • Signaling Pathways & Mechanisms: CEACAM5 is a glycosylphosphatidylinositol-anchored cell surface glycoprotein involved in cell adhesion, intracellular signaling, and tumor progression. It can interact with various proteins to modulate cell growth, differentiation, and immune responses. Overexpression is common in many cancers, including colorectal cancer, where it contributes to cell proliferation, survival, and metastasis. It can activate signaling pathways like MAPK/ERK and PI3K/Akt.
   • Relevant Therapeutic Agents: CEACAM5 is a long-standing and established biomarker for colorectal cancer. Therapeutic antibodies targeting CEACAM5, such as labetuzumab and the antibody-drug conjugate (ADC) sacituzumab govitecan (which targets Trop-2 but CEACAM5 is also a common target for ADCs), have been developed and evaluated in clinical trials for solid tumors, including CRC.
   • Supporting Evidence: Elevated CEACAM5 levels are associated with poor prognosis in CRC. Its role in tumor progression and as a circulating biomarker (CEA) is well-established. PubMed search: CEACAM5 colorectal cancer therapy
2. EPCAM (Epithelial Cell Adhesion Molecule)
   • Signaling Pathways & Mechanisms: EPCAM is a transmembrane glycoprotein primarily involved in cell-cell adhesion, proliferation, and differentiation of epithelial cells. In cancer, its overexpression is linked to enhanced cell proliferation, migration, invasion, and metastatic potential, often through interactions with Wnt signaling components and activation of the EGFR pathway. It acts as an oncogene in many carcinomas.
   • Relevant Therapeutic Agents: EPCAM is a widely recognized pan-carcinoma antigen and has been targeted with various immunotherapeutic approaches, including monoclonal antibodies (e.g., Catumaxomab), CAR T-cell therapies, and ADCs, for different epithelial cancers, including CRC.
   • Supporting Evidence: EPCAM overexpression is frequently observed in CRC and is considered a marker for circulating tumor cells and a prognostic indicator. GeneCards: EPCAM
3. CD47 (CD47 Molecule)
   • Signaling Pathways & Mechanisms: CD47 is a widely expressed transmembrane protein that interacts with SIRPα (Signal Regulatory Protein Alpha) on phagocytic cells, sending a "don't eat me" signal that inhibits phagocytosis. In cancer, its overexpression allows tumor cells to evade immune surveillance by preventing their engulfment by macrophages. It also plays roles in cell adhesion, migration, and apoptosis.
   • Relevant Therapeutic Agents: Anti-CD47 antibodies and CD47-blocking agents are a promising class of immune checkpoint inhibitors currently in various stages of clinical development for solid tumors and hematological malignancies, including CRC. These agents aim to unleash the innate immune response against cancer cells.
   • Supporting Evidence: CD47 overexpression is a common immune evasion mechanism in many cancers, correlating with poor prognosis. UniProt: CD47, PubMed search: CD47 colorectal cancer therapy

Potential Therapeutic Targets

These markers are highly expressed in the tumor context, suggesting a significant role in cancer pathology, and represent promising candidates for novel therapeutic strategies.

1. DDR1 (Discoidin Domain Receptor Tyrosine Kinase 1)
   • Signaling Pathways & Mechanisms: DDR1 is a receptor tyrosine kinase activated by collagen. It plays a crucial role in cell adhesion, migration, invasion, and tissue remodeling. In cancer, DDR1 can promote tumor cell survival, proliferation, and metastasis by regulating pathways such as MAPK/ERK, PI3K/Akt, and NF-κB, often in response to the altered extracellular matrix found in the tumor microenvironment.
   • Relevant Therapeutic Agents: DDR1 inhibitors are under investigation as potential anti-cancer agents, particularly for cancers with significant desmoplastic reactions or collagen remodeling. Given its role in modulating tumor-stroma interactions, it could be a target for combination therapies.
   • Supporting Evidence: DDR1 overexpression has been linked to poor prognosis and increased invasiveness in various cancers, including CRC. GeneCards: DDR1
2. EPHA2 (EPH Receptor A2)
   • Signaling Pathways & Mechanisms: EPHA2 is a receptor tyrosine kinase that binds to ephrin-A ligands. It is involved in cell-cell communication, cell adhesion, migration, and tissue organization. In many cancers, EPHA2 is frequently overexpressed and can act as an oncogene, promoting proliferation, survival, and angiogenesis through various signaling cascades, often in a ligand-independent manner or by interacting with other growth factor receptors.
   • Relevant Therapeutic Agents: Inhibitors targeting EPHA2, as well as antibody-drug conjugates, are being explored as potential cancer therapeutics. Its role in angiogenesis and metastasis makes it an attractive target.
   • Supporting Evidence: EPHA2 overexpression is common in CRC and is associated with tumor progression and metastasis. UniProt: EPHA2
3. MUC4 (Mucin 4, Cell Surface Associated)
   • Signaling Pathways & Mechanisms: MUC4 is a large transmembrane mucin glycoprotein that can form a protective barrier, but also plays diverse roles in cell signaling. In cancer, MUC4 overexpression is often associated with aggressive tumor behavior. It can interact with and stabilize growth factor receptors like ErbB2 (HER2), leading to constitutive activation of downstream pathways such as PI3K/Akt and MAPK/ERK, thereby promoting cell proliferation, survival, and resistance to apoptosis. It also mediates immune evasion and metastasis.
   • Relevant Therapeutic Agents: Targeting MUC4, potentially with antibodies or small molecules that disrupt its interactions with growth factor receptors, is an area of active research. Given its role in stabilizing HER2, it could be relevant in HER2-positive CRC or as a target for ADCs.
   • Supporting Evidence: MUC4 overexpression is a common feature in several adenocarcinomas, including aggressive forms of CRC, and is often linked to poor prognosis. PubMed search: MUC4 colorectal cancer therapy

Clinical or Translational Implications

The strong upregulation of specific surfaceome markers in Intestinal Epithelial cells within the 'Tumor' condition of colorectal cancer samples provides crucial insights for clinical translation.

• Diagnostic and Prognostic Biomarkers: Markers like CEACAM5, CEACAM6, and EPCAM, already known for their utility in CRC, are reinforced by this single-cell data. Their consistent high expression across tumor cells suggests their continued relevance as diagnostic, prognostic, and potentially predictive biomarkers for guiding treatment decisions.

Therapeutic Development

• Established Targets: The robust expression of established therapeutic targets such as CEACAM5, EPCAM, and CD47 in tumor cells indicates that immunotherapies or targeted agents directed against these molecules are highly relevant for CRC. Further investigation into patient stratification based on expression levels and combination therapies involving these targets is warranted.
• Novel Therapeutic Avenues: The identified potential targets like DDR1, EPHA2, and MUC4 offer promising new avenues for drug development. Their roles in critical cancer processes (cell adhesion, invasion, growth factor signaling, immune evasion) make them attractive for developing novel small molecule inhibitors, therapeutic antibodies, or antibody-drug conjugates. Experimental validation in CRC models and clinical trials would be the next critical steps to assess their efficacy and safety.

• Precision Medicine: The patient-specific variability observed in marker expression (e.g., some tumor samples showing higher expression of certain markers than others) emphasizes the need for personalized approaches. Single-cell analysis, such as this, can help identify subgroups of patients who might benefit most from therapies targeting specific surface markers. This data could inform the design of future clinical trials, ensuring that patients are selected based on the molecular profiles of their tumor cells.

16. Macrophage Condition-Specific Surfaceome Markers in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes condition-specific surfaceome markers for Macrophages across "Adj_normal" (adjacent normal) and "Tumor" tissue samples in a colorectal cancer dataset. The dot plot illustrates the mean expression level (color intensity) and the fraction of cells expressing each marker (dot size) for individual samples grouped by their condition. Markers were selected based on differential expression criteria (nz_pct_score and nz_pct FC), focusing exclusively on surfaceome genes. This provides insights into how macrophage surface phenotypes differ between normal and tumor microenvironments, highlighting potential targets for therapeutic intervention.

Visual Summary

The dot plot effectively visualizes the expression patterns of 80 surfaceome markers in Macrophages across 23 individual samples (4 "Adj_normal" and 19 "Tumor" samples).

• Condition-Specific Expression Patterns: A clear distinction is observed between Macrophages from "Adj_normal" and "Tumor" conditions.
  • Adj_normal Macrophages: Tend to express a set of markers on the left side of the plot, including MS4A6A, HLA-DMB, HLA-DQA2, TMEM123, TMEM219, JAML, TNFRSF1B, CSF1R, and CD4. These markers show high mean expression and are prevalent across most "Adj_normal" samples.
  • Tumor Macrophages: Exhibit a dramatically different expression profile. They are characterized by high expression and prevalence of markers on the right side of the plot, such as GPNMB, FCGR2A, FCGR3A, CD9, OLR1, NRP2, CD40, CD151, ADAM9, AXL, MSR1, and CD36. These markers are largely absent or lowly expressed in "Adj_normal" macrophages.
• Heterogeneity within Tumor Samples: While a general pattern emerges for "Tumor" macrophages, there is notable variability among individual tumor samples (e.g., SMC07-T, SMC25-T show stronger expression of certain tumor-associated markers compared to SMC10-T or SMC21-T). This highlights the patient-specific nature of the tumor microenvironment.
• Marker Abundance and Expression: The dot size (fraction of cells) and color intensity (mean expression) provide a comprehensive view. Many tumor-associated markers are not only highly expressed but also present in a large fraction of macrophages within the tumor samples, suggesting a widespread phenotypic shift.
• Bar Plots on the Right: The small bar plots on the far right indicate the total number of cells per sample, offering context for the sample-specific marker expression.

Biological Interpretation

Macrophages are key components of the tumor microenvironment (TME) in colorectal cancer. They can adopt diverse functional phenotypes, broadly categorized as pro-inflammatory (M1-like) or pro-tumorigenic (M2-like) Tumor-Associated Macrophages (TAMs). The observed differential surface marker expression reflects these functional shifts between normal and tumor contexts.

Markers Enriched in "Adj_normal" Macrophages:

The markers enriched in adjacent normal tissue macrophages generally suggest a homeostatic or immune-regulatory role, potentially involved in antigen presentation and immune surveillance.

• HLA-DMB, HLA-DQA2: These are components of the MHC Class II complex, crucial for presenting exogenous antigens to CD4+ T cells and initiating adaptive immune responses. Their high expression in normal tissue macrophages suggests a role in maintaining immune surveillance. In the tumor context, downregulation or altered expression of MHC Class II molecules can contribute to immune evasion. GeneCards: HLA-DMB, GeneCards: HLA-DQA2
• CSF1R: Colony Stimulating Factor 1 Receptor. While crucial for macrophage development and survival, its high expression in normal tissue macrophages indicates responsiveness to CSF1, a cytokine that drives macrophage differentiation and survival. CSF1R signaling is often co-opted by tumors to recruit and polarize TAMs. GeneCards: CSF1R
• CD4: A co-receptor primarily found on T helper cells, but also expressed on a subset of macrophages and dendritic cells. Its presence on macrophages from normal tissue might indicate specific functional subsets or states of immune readiness. GeneCards: CD4

Markers Enriched in "Tumor" Macrophages:

The strong upregulation of specific surface markers in tumor-associated macrophages points towards their altered phenotype and their contribution to tumor progression, angiogenesis, and immune suppression in colorectal cancer. These markers represent promising therapeutic targets.

• GPNMB (Glycoprotein Non-Metastatic B): Highly expressed in "Tumor" macrophages.
  • Signaling Pathways: GPNMB is involved in cellular adhesion, motility, and immune modulation. It can promote tumor growth and metastasis. Its interaction with integrins has been suggested.
  • Role in TME: GPNMB+ TAMs are often associated with an immunosuppressive and pro-tumorigenic phenotype, promoting angiogenesis, tumor cell survival, and invasion. In CRC, it might contribute to the unique inflammatory and fibrotic TME.
  • Therapeutic Potential: Its surface localization and association with aggressive cancer make GPNMB an attractive target for antibody-drug conjugates (ADCs) or other targeted therapies to eliminate pro-tumorigenic macrophages or inhibit their functions.
  • Relevant Therapeutic Agents: Glembatumumab vedotin (a GPNMB-targeting ADC) has been investigated in other cancers. GeneCards: GPNMB
• FCGR2A (CD32a) and FCGR3A (CD16a): Fc Gamma Receptors, showing strong expression in "Tumor" macrophages.
  • Signaling Pathways: These receptors bind to the Fc portion of immunoglobulins, mediating diverse immune functions including phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), and antigen presentation. They activate downstream signaling pathways upon ligand binding.
  • Role in TME: While often associated with activating immune responses (FCGR3A is known for ADCC by NK cells, also on macrophages), certain FcRs on TAMs can also mediate immune suppression or clear immune complexes, contributing to an altered immune response. The specific context of their co-expression and cellular environment dictates their role.
  • Therapeutic Potential: Their expression could be leveraged by therapeutic antibodies designed to engage these receptors on TAMs, either to induce direct killing of TAMs (e.g., via ADCC if FCGR3A is active) or to reprogram their function. GeneCards: FCGR2A, GeneCards: FCGR3A
• NRP2 (Neuropilin-2): Elevated in "Tumor" macrophages.
  • Signaling Pathways: NRP2 acts as a co-receptor for various ligands, including VEGF and semaphorins, playing roles in angiogenesis, lymphangiogenesis, and neuronal guidance. In immune cells, it can modulate immune cell trafficking and function.
  • Role in TME: NRP2 on TAMs can promote angiogenesis and lymphangiogenesis within the tumor, supporting tumor growth and metastasis. It can also influence macrophage polarization and suppress anti-tumor immunity.
  • Therapeutic Potential: Targeting NRP2 could disrupt pro-angiogenic signaling and potentially modulate the immunosuppressive functions of TAMs in CRC. GeneCards: NRP2
• CD36: Highly expressed in "Tumor" macrophages.
  • Signaling Pathways: CD36 is a scavenger receptor involved in lipid metabolism (uptake of oxidized LDL, fatty acids), angiogenesis, and immune recognition.
  • Role in TME: CD36 expression on TAMs is often associated with an M2-like, pro-tumorigenic phenotype. It can promote lipid uptake, which fuels TAM survival and suppressive functions. It also plays a role in angiogenesis and metastasis. In CRC, CD36+ TAMs may contribute to metabolic reprogramming within the TME.
  • Therapeutic Potential: Inhibiting CD36 could starve TAMs of essential lipids, impairing their function and potentially reprogramming them to a less pro-tumorigenic state. GeneCards: CD36
• AXL (AXL Receptor Tyrosine Kinase): Notably expressed in "Tumor" macrophages.
  • Signaling Pathways: AXL is a receptor tyrosine kinase that binds GAS6, promoting cell survival, proliferation, migration, and angiogenesis.
  • Role in TME: AXL is frequently expressed on TAMs and can contribute to immune evasion, angiogenesis, and resistance to therapy. Its activation promotes an immunosuppressive environment and can be involved in efferocytosis (clearance of apoptotic cells).
  • Therapeutic Potential: AXL inhibitors are being explored in various cancers to target both tumor cells and TAMs, aiming to reduce tumor growth and enhance anti-tumor immunity. GeneCards: AXL
• CD9: Ubiquitously expressed in "Tumor" macrophages.
  • Signaling Pathways: CD9 is a tetraspanin involved in cell adhesion, motility, and signal transduction through interactions with other surface proteins.
  • Role in TME: On macrophages, CD9 can influence cell-cell interactions and migration within the TME. It may contribute to tumor progression by facilitating stromal cell interactions.
  • Therapeutic Potential: Targeting tetraspanins like CD9 is complex due to their diverse interactions, but understanding its role could offer insights into macrophage-stromal interactions. GeneCards: CD9
• MSR1 (Macrophage Scavenger Receptor 1): Present in "Tumor" macrophages.
  • Signaling Pathways: MSR1 is a scavenger receptor involved in the uptake of modified lipoproteins and pathogens. It can modulate inflammatory responses.
  • Role in TME: MSR1 is often associated with alternatively activated (M2-like) macrophages and can contribute to immune suppression and tissue remodeling within the TME.
  • Therapeutic Potential: While less explored as a direct target, MSR1's role in TAM function suggests it could be a marker for pro-tumorigenic subsets. GeneCards: MSR1

Clinical or Translational Implications

The identification of these condition-specific surfaceome markers on macrophages in colorectal cancer has significant clinical and translational implications:

1. Diagnostic and Prognostic Biomarkers: The distinct expression profiles between "Adj_normal" and "Tumor" macrophages suggest that these markers could serve as diagnostic indicators for CRC or as prognostic factors, especially in liquid biopsies or tissue analysis. For instance, high expression of GPNMB or AXL on macrophages within tumor biopsies could correlate with disease progression or therapeutic response.
2. Therapeutic Targets for Macrophage Reprogramming/Depletion:
   • The prominent expression of surface receptors like GPNMB, AXL, NRP2, CD36, FCGR2A, and FCGR3A on TAMs offers multiple avenues for targeted therapies.
   • Antibody-drug conjugates (ADCs): These could be developed to deliver cytotoxic payloads specifically to GPNMB+, AXL+, or CD36+ TAMs, effectively depleting these pro-tumorigenic cells.
   • Receptor inhibitors: Small molecule inhibitors against AXL could block crucial pro-survival and pro-angiogenic signaling pathways in TAMs and potentially tumor cells.
   • Fc-engineered antibodies: Therapeutic antibodies targeting tumor cells could be engineered to modulate the interaction with FcγRs on TAMs, promoting or inhibiting phagocytosis and leading to TAM reprogramming.
   • Metabolic inhibitors: Targeting CD36 could disrupt the lipid metabolism of TAMs, impairing their function and viability.
3. Understanding Macrophage Plasticity: The data highlight the profound phenotypic changes macrophages undergo in the CRC TME. Further research into the upstream signals driving the expression of these markers (e.g., cytokines, growth factors, metabolic cues) could reveal mechanisms to reprogram TAMs towards an anti-tumorigenic state.
4. Combination Therapies: Targeting specific macrophage surface markers could be synergistic with existing immunotherapies (e.g., checkpoint inhibitors) or conventional chemotherapies, by alleviating immune suppression or hindering tumor growth. For instance, reducing TAM burden or reprogramming their function could enhance T cell-mediated anti-tumor responses.

Overall, this analysis provides a molecular foundation for developing novel macrophage-targeted strategies to improve outcomes for colorectal cancer patients.

17. Fibroblast Condition-Specific Surfaceome Marker Analysis in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies surfaceome markers differentially expressed in Fibroblast cells between 'Adj_normal' and 'Tumor' conditions within a human Colon single-cell RNA-seq dataset. The goal is to highlight potential molecular features distinguishing fibroblasts in healthy tissue from those activated within the tumor microenvironment (TME), commonly known as Cancer-Associated Fibroblasts (CAFs). The identified markers are interpreted for their biological roles, their contribution to the TME in the context of Colorectal Cancer, and their potential as therapeutic targets.

Visual Summary

The dot plot visualizes the expression of 53 surfaceome markers across various patient samples grouped by condition (Adj_normal vs. Tumor). Each dot's color intensity represents the mean expression level of a marker within a sample group (darker red indicates higher expression), and its size indicates the fraction of cells expressing that marker within the group (larger dot indicates higher prevalence).

• Distinct Condition-Specific Expression: The plot clearly shows two main clusters of markers. The left panel, highlighted by a red box, displays markers predominantly expressed by Fibroblasts in 'Adj_normal' samples. Conversely, the right panel, also highlighted by a red box, shows markers highly expressed in Fibroblasts from 'Tumor' samples.
• "Adj_normal" Fibroblast Markers: Genes such as PROCR, TFPI, IL6ST, and SCARA5 exhibit high mean expression and prevalence across most 'Adj_normal' samples, with minimal expression in 'Tumor' samples. These markers likely characterize quiescent or homeostatic fibroblasts.
• "Tumor" Fibroblast Markers (CAFs): A robust set of markers, including FAP, PDGFRB, PLAUR, ITGAV, CD276, ITGA5, EDNRA, and PTK7, demonstrate high mean expression and widespread prevalence in 'Tumor' samples, with very low or no expression in 'Adj_normal' samples. These are hallmark markers of activated CAFs, indicating their distinct phenotypic shift within the tumor microenvironment.
• Sample-Level Consistency: Within each condition, there is generally high consistency in marker expression patterns across individual patient samples, although some variability in expression intensity and cell fraction is observed.

Biological Interpretation

Markers of Fibroblasts in Adjacent Normal Tissue

These markers are indicative of fibroblasts potentially maintaining tissue homeostasis or exhibiting a less activated phenotype compared to CAFs.

PROCR (Protein C Receptor):

• Signaling Pathways: Primarily involved in the protein C pathway, activating protein C (APC) which has anti-coagulant, anti-inflammatory, and cytoprotective effects through protease-activated receptor 1 (PAR1) signaling.
• Role in TME: In normal colon tissue, PROCR on fibroblasts may contribute to maintaining vascular integrity, controlling inflammation, and promoting tissue repair mechanisms. Its high expression in adjacent normal tissue suggests a role in homeostatic maintenance rather than pro-tumorigenic activation.
• Therapeutic Target Potential: Not typically a direct therapeutic target for pro-tumorigenic fibroblasts, but its modulation could influence the anti-inflammatory and anti-coagulant balance in the local microenvironment, which can indirectly affect cancer progression.
• Relevant Therapeutic Agents: Therapeutic approaches targeting the protein C system exist (e.g., recombinant activated protein C), but are not specifically developed for fibroblast-targeted cancer therapy.
• Other Pertinent Information: Also known as EPCR, it is commonly found on endothelial cells and specific stem cell populations. Its presence on fibroblasts suggests a distinct subpopulation with roles beyond structural support. GeneCards link for PROCR

TFPI (Tissue Factor Pathway Inhibitor):

• Signaling Pathways: A potent physiological inhibitor of the Tissue Factor (TF)-Factor VIIa complex, thereby regulating the extrinsic coagulation pathway. It also interacts with lipoproteins and cell surface components, potentially influencing cell adhesion and migration.
• Role in TME: In normal fibroblasts, TFPI contributes to maintaining vascular integrity and preventing pathological coagulation. It may also have anti-angiogenic properties. High expression in adjacent normal fibroblasts suggests a role in maintaining a non-thrombogenic and quiescent microenvironment, contrasting with the pro-coagulant state often seen in tumors.
• Therapeutic Target Potential: Enhancing TFPI activity could theoretically reduce tumor-associated thrombosis and angiogenesis. However, direct fibroblast-targeted therapies exploiting TFPI are not currently common.
• Relevant Therapeutic Agents: Recombinant TFPI has been investigated for its anti-coagulant properties, but not as a primary anti-cancer agent targeting stromal cells.
• Other Pertinent Information: Loss or reduction of TFPI in the tumor microenvironment can contribute to a pro-coagulant, pro-angiogenic, and pro-metastatic state. GeneCards link for TFPI

IL6ST (Interleukin 6 Signal Transducer / gp130):

• Signaling Pathways: A common signal-transducing subunit for receptor complexes of the IL-6 cytokine family (e.g., IL-6, IL-11, LIF). Upon ligand binding, gp130 dimerizes, activating the JAK/STAT (particularly STAT3), MAPK, and PI3K pathways, influencing cell proliferation, survival, differentiation, and inflammation.
• Role in TME: While often associated with pro-tumorigenic inflammation and CAF activation in the TME, its basal expression in adjacent normal fibroblasts may indicate their capacity to respond to inflammatory cues to maintain tissue homeostasis. However, dysregulated or persistent activation of IL-6/gp130 signaling can drive CAF activation and an immunosuppressive TME.
• Therapeutic Target Potential: Targeting gp130 or its downstream pathways (e.g., JAK/STAT3) is a recognized strategy in cancer, particularly where IL-6 signaling is prominent. Inhibition can reduce CAF-mediated tumor support and immune suppression.
• Relevant Therapeutic Agents: Monoclonal antibodies against IL-6 (e.g., Siltuximab) or its receptor (e.g., Tocilizumab), and JAK/STAT inhibitors (e.g., Ruxolitinib) are used in inflammatory diseases and some cancers.
• Other Pertinent Information: gp130 is crucial for normal physiological processes, so therapeutic targeting requires careful consideration of potential off-target effects. GeneCards link for IL6ST

Markers of Fibroblasts in Tumor Tissue (Cancer-Associated Fibroblasts - CAFs)

These markers highlight the activated and pro-tumorigenic phenotype of fibroblasts within the colorectal cancer microenvironment.

FAP (Fibroblast Activation Protein alpha):

• Signaling Pathways: FAP is a serine protease with dipeptidyl peptidase and endopeptidase activities. It degrades specific extracellular matrix (ECM) components like collagen and gelatin, and can modulate growth factors. It also interacts with other cell surface proteins and signaling pathways, promoting cell migration and invasion.
• Role in TME: FAP is a canonical marker of activated CAFs in colorectal cancer. FAP+ CAFs extensively remodel the ECM, creating a stiff, desmoplastic, and immunosuppressive TME that fosters tumor growth, invasion, metastasis, and resistance to therapy. They also secrete pro-tumorigenic factors.
• Therapeutic Target Potential: High potential due to its restricted expression in the tumor stroma and its functional contribution to tumor progression. Strategies include enzymatic inhibition, FAP-targeted immunotherapies (e.g., CAR-T cells, bispecific antibodies), and FAP-targeted drug delivery systems.
• Relevant Therapeutic Agents: Small molecule FAP inhibitors, FAP-targeted antibodies (e.g., Sibrotuzumab, though with limited clinical success), FAP-targeted radioligands for imaging and therapy are under investigation.
• Other Pertinent Information: FAP expression is largely absent in normal adult tissues but upregulated in pathological conditions like cancer, wound healing, and fibrosis, making it a highly selective therapeutic target. GeneCards link for FAP

PDGFRB (Platelet-Derived Growth Factor Receptor Beta):

• Signaling Pathways: A receptor tyrosine kinase (RTK) that is activated by PDGF ligands (e.g., PDGF-BB). Upon ligand binding, it dimerizes and autophosphorylates, initiating intracellular signaling cascades including PI3K/Akt/mTOR, MAPK/ERK, and STAT pathways, promoting cell proliferation, survival, migration, and angiogenesis.
• Role in TME: PDGFRB signaling is crucial for CAF activation and recruitment. Tumor-derived PDGF can activate PDGFRB on fibroblasts, driving their proliferation, differentiation into CAFs, and production of ECM components and growth factors, leading to desmoplasia and an immunosuppressive TME in colorectal cancer.
• Therapeutic Target Potential: A well-established therapeutic target in oncology due to its central role in stromal remodeling and angiogenesis. Inhibition can reduce CAF activity, normalize tumor vasculature, and potentially improve drug delivery.
• Relevant Therapeutic Agents: Tyrosine kinase inhibitors (TKIs) such as Imatinib and Sunitinib, which target PDGFRB (among other kinases), are clinically approved for various cancers. More selective PDGFRB inhibitors are also being developed.
• Other Pertinent Information: Aberrant PDGFRB signaling is implicated in numerous cancers and fibrotic disorders. GeneCards link for PDGFRB

PLAUR (Urokinase Plasminogen Activator Receptor / uPAR):

• Signaling Pathways: Binds urokinase plasminogen activator (uPA), localizing plasminogen activation to the cell surface, leading to degradation of the ECM. uPAR also interacts with integrins and G-protein coupled receptors, activating pathways like MAPK/ERK and PI3K/Akt, promoting cell adhesion, migration, proliferation, and survival.
• Role in TME: Upregulated on CAFs in colorectal cancer, uPAR facilitates ECM degradation, which is critical for tumor cell invasion and metastasis. It also promotes angiogenesis and enhances the migratory and invasive phenotype of CAFs themselves, contributing to an aggressive tumor phenotype.
• Therapeutic Target Potential: Targeting uPAR can inhibit tumor cell invasion, metastasis, and angiogenesis by blocking its interaction with uPA and its downstream signaling, thereby impairing CAF functions.
• Relevant Therapeutic Agents: Several agents designed to target uPAR, including antibodies and small molecule inhibitors that interfere with uPA-uPAR binding, are in preclinical and early clinical development.
• Other Pertinent Information: uPAR is a glycosylphosphatidylinositol (GPI)-anchored protein, meaning it lacks a transmembrane domain and signals primarily through its interactions with other cell surface receptors. GeneCards link for PLAUR

ITGAV (Integrin Alpha V):

• Signaling Pathways: Forms heterodimers with various beta integrin subunits (e.g., ITGB3, ITGB5) to create receptors for diverse ECM proteins (e.g., vitronectin, fibronectin, osteopontin). Integrin binding activates intracellular signaling cascades, including FAK, Src, and Rho GTPases, influencing cell adhesion, migration, proliferation, and survival.
• Role in TME: αV integrins are highly expressed on CAFs and are crucial for their interaction with the remodeled ECM. They mediate cell migration, invasion, and contraction, contributing to tissue stiffness, promoting tumor progression, angiogenesis, and metastasis in colorectal cancer. They facilitate the deposition and organization of a pro-tumorigenic ECM.
• Therapeutic Target Potential: Integrins are attractive therapeutic targets due to their surface accessibility and vital roles in cell-ECM interactions. Inhibiting αV integrins could disrupt CAF function, reduce tumor cell invasion and metastasis, and inhibit angiogenesis.
• Relevant Therapeutic Agents: Integrin inhibitors, such as Cilengitide (targeting αVβ3 and αVβ5 integrins), have been evaluated in clinical trials, though specific efficacy can vary depending on tumor type and context.
• Other Pertinent Information: Given the broad physiological importance of integrins, highly specific targeting is crucial to minimize off-target effects. GeneCards link for ITGAV

CD276 (B7-H3):

• Signaling Pathways: A member of the B7 family of immune checkpoint molecules. While its exact receptor is debated, it is known to inhibit T cell activation and promote tumor immune evasion. It may also directly enhance tumor cell proliferation, migration, and angiogenesis through both immune-dependent and -independent mechanisms.
• Role in TME: Expressed on CAFs, CD276 contributes to the immunosuppressive TME by inhibiting anti-tumor T cell responses, allowing colorectal cancer cells to escape immune surveillance. Its presence on fibroblasts indicates their active participation in shaping an immune-privileged environment.
• Therapeutic Target Potential: High potential as an immune checkpoint target. Antibodies blocking CD276 could reverse T cell inhibition and enhance anti-tumor immunity. CAR-T cells and antibody-drug conjugates (ADCs) targeting CD276 are under active investigation.
• Relevant Therapeutic Agents: Monoclonal antibodies targeting B7-H3 (e.g., Enoblituzumab) are currently in clinical trials for various cancers.
• Other Pertinent Information: CD276 expression is often upregulated in many cancers and correlates with poor prognosis, making it a promising candidate for immunotherapy. GeneCards link for CD276

EDNRA (Endothelin Receptor Type A):

• Signaling Pathways: A G protein-coupled receptor (GPCR) that binds Endothelin-1 (ET-1). Activation leads to downstream signaling through PLC/IP3/DAG, PKC, and MAPK pathways, affecting cell proliferation, survival, migration, and vasoconstriction.
• Role in TME: The ET-1/EDNRA axis is frequently dysregulated in cancer. In the colorectal TME, ET-1 secreted by tumor cells can activate EDNRA on CAFs, promoting their proliferation, activation, and ECM production, thereby contributing to desmoplasia and tumor progression. It can also promote angiogenesis and modulate immune responses.
• Therapeutic Target Potential: Inhibition of EDNRA signaling can reduce CAF activation, suppress tumor growth, and potentially improve the efficacy of other anti-cancer therapies.
• Relevant Therapeutic Agents: EDNRA antagonists (e.g., Atrasentan, Ambrisentan) are used in other diseases (e.g., pulmonary arterial hypertension) and have been explored in oncology, with varying success depending on the cancer type.
• Other Pertinent Information: EDNRA plays a vital role in cardiovascular function, necessitating careful consideration of potential systemic side effects when used in cancer therapy. GeneCards link for EDNRA

PTK7 (Protein Tyrosine Kinase 7):

• Signaling Pathways: An atypical receptor tyrosine kinase that lacks intrinsic catalytic activity but acts as a scaffolding protein or co-receptor. It is involved in regulating Wnt/PCP (planar cell polarity) signaling, cell migration, and invasiveness.
• Role in TME: Overexpressed in various cancers and on CAFs, PTK7 promotes tumor cell migration, invasion, and metastasis, likely by modulating Wnt signaling and cell adhesion. On CAFs, it may contribute to their migratory capacity and their ability to actively remodel the TME.
• Therapeutic Target Potential: Due to its overexpression in cancer and its role in invasiveness, PTK7 is being investigated as a therapeutic target, particularly for antibody-drug conjugates (ADCs) which deliver cytotoxic agents specifically to PTK7-expressing cells.
• Relevant Therapeutic Agents: ADCs targeting PTK7 are currently in preclinical and clinical development for various solid tumors.
• Other Pertinent Information: PTK7 is also important during embryonic development. Its selective overexpression in adult cancers makes it an attractive target. GeneCards link for PTK7

Clinical or Translational Implications

The distinct surfaceome expression profiles identified provide critical insights into the phenotypic adaptation of fibroblasts in the colorectal cancer microenvironment.

1. Biomarker Potential: The identified CAF-specific markers (e.g., FAP, PDGFRB, PLAUR, CD276) could serve as valuable biomarkers for diagnosing colorectal cancer, assessing disease progression, or predicting response to therapy. Detection of these markers on circulating fibroblasts or in tissue biopsies could aid in patient stratification.
2. Therapeutic Targeting of CAFs: The robust expression of genes like FAP, PDGFRB, CD276, ITGAV, PLAUR, EDNRA, and PTK7 on tumor-associated fibroblasts, coupled with their minimal expression on adjacent normal fibroblasts, makes them highly attractive targets for developing CAF-specific therapies. Targeting CAFs could:
   • Reduce Tumor Growth and Metastasis: By inhibiting their ability to remodel the ECM, support tumor cell proliferation, and promote invasion.
   • Overcome Immunosuppression: By targeting molecules like CD276, which contribute to an immune-evasive TME, potentially sensitizing tumors to existing immunotherapies.
   • Improve Drug Delivery: By normalizing the tumor stroma, which can impede the penetration of chemotherapeutic agents and immunotherapies.
3. Combination Therapies: CAF-targeted therapies could be particularly effective when combined with conventional chemotherapy, radiation therapy, or immunotherapies, aiming to dismantle the protective and pro-tumorigenic stromal barrier.
4. Minimizing Off-Target Effects: The specific expression of these markers in tumor fibroblasts, as opposed to normal tissue fibroblasts, suggests that therapies directed against them might have fewer systemic side effects, improving the therapeutic window.
5. Understanding CAF Heterogeneity: The presence of multiple distinct CAF markers suggests functional heterogeneity among CAFs. Further studies are needed to understand if specific subsets of CAFs, defined by these markers, contribute differentially to colorectal cancer progression and if combinatorial targeting strategies are warranted.

18. Condition-Specific Surfaceome Markers on CD4+ T cells in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers in CD4+ T cells, comparing 'Adj_normal' (adjacent normal tissue) and 'Tumor' conditions from human colon single-cell RNA-seq data. The goal is to highlight molecular differences that may explain T cell function and potential therapeutic targets in colorectal cancer. Only surfaceome markers were considered, with a maximum of 40 markers per condition, utilizing specific nz_pct_score, nz_pct_test_cutoff, and fc_cutoff thresholds for marker identification.

Visual Summary

The dot plot displays the expression patterns of 21 surfaceome markers across various patient samples, categorized into 'Adj_normal' and 'Tumor' conditions.

• Mean Expression: Represented by the color intensity (darker red indicates higher mean expression).
• Fraction of Cells: Represented by the size of the dot (larger dot indicates a higher percentage of cells expressing the marker).
• Clustering: Samples are clustered by condition, clearly showing distinct marker expression profiles between 'Adj_normal' and 'Tumor' CD4+ T cells.

Distinct Marker Sets:

• A group of markers including CD48, GPR183, MYADM, SLC2A3, PTGIR, GLIPR1, CD55, ATP1A1, ADGRE5, and TRAT1 shows high mean expression and high cell fraction specifically in CD4+ T cells from 'Adj_normal' samples. These markers are largely absent or expressed at very low levels in 'Tumor' samples.
• Conversely, markers such as CD74, LY6E, TNFRSF4, TNFRSF18, TIGIT, TNFRSF25, HLA-DPB1, and HLA-DPA1 are predominantly and highly expressed in CD4+ T cells from 'Tumor' samples, with minimal to no expression in 'Adj_normal' samples.

This clear segregation indicates distinct functional states or populations of CD4+ T cells residing in the healthy vs. tumor microenvironment.

Biological Interpretation

The observed differential expression of surfaceome markers suggests distinct roles and states of CD4+ T cells in the adjacent normal colon tissue compared to the colorectal tumor microenvironment (TME).

Markers Enriched in 'Adj_normal' CD4+ T cells

These markers may represent a homeostatic, quiescent, or inflammatory but non-tumor-driven state of CD4+ T cells. Their downregulation in the TME could indicate altered T cell function, migration, or a shift in T cell subsets within the tumor.

CD48 (SLAMF2):

• Signaling Pathways: A member of the SLAM family of receptors, CD48 participates in T cell activation and adhesion through interaction with CD244 (2B4). It can induce both stimulatory and inhibitory signals depending on the cell type and context, often involving adaptor proteins like SAP.
• Role in TME: In a healthy context, CD48 contributes to effective immune cell interactions. Its diminished expression in the TME might reflect dysregulated cell-cell communication, potentially impairing anti-tumor responses.
• Therapeutic Potential: While primarily involved in normal immune function, its altered expression in tumor might indicate a disruption in immune surveillance. Direct targeting is less likely, but understanding its role could inform combination therapies.
• Relevant Agents: No direct therapeutic agents targeting CD48 are widely used in oncology.
• Reference: GeneCards: CD48

GPR183 (EBI2):

• Signaling Pathways: GPR183 is a G protein-coupled receptor (GPCR) that binds oxysterols. It signals through Gi-type G proteins, leading to inhibition of adenylate cyclase and activation of MAPK pathways, critical for immune cell migration.
• Role in TME: It guides the migration of various immune cells, including T cells, B cells, and dendritic cells, to lymphoid organs. Its high expression in normal tissue CD4+ T cells might reflect their homing capabilities or specific localization within healthy intestinal lymphoid structures.
• Therapeutic Potential: Modulating GPR183 activity could potentially redirect immune cell trafficking to or away from tumors.
• Relevant Agents: No approved therapeutic agents, but antagonists are explored for autoimmune diseases.
• Reference: PubMed search: GPR183 immune cell migration

SLC2A3 (GLUT3):

• Signaling Pathways: As a glucose transporter, GLUT3 facilitates glucose uptake, a critical metabolic substrate for T cell activation and function. Its activity is regulated by various kinases (e.g., PI3K/Akt pathway) that sense nutrient availability.
• Role in TME: Activated T cells heavily rely on glycolysis, requiring high glucose uptake. Its presence in normal tissue CD4+ T cells suggests a metabolically active state or readiness for activation. Downregulation in tumor T cells could indicate metabolic suppression or exhaustion in the nutrient-deprived TME.
• Therapeutic Potential: Targeting glucose metabolism in T cells in the TME could enhance anti-tumor immunity by restoring their metabolic fitness.
• Relevant Agents: No specific GLUT3 modulators for cancer immunotherapy, but metabolic reprogramming is an active area of research.
• Reference: PubMed search: T cell metabolism GLUT3 cancer

CD55 (DAF):

• Signaling Pathways: CD55 is a glycosylphosphatidylinositol (GPI)-anchored protein that regulates the complement system, inhibiting C3 convertase formation. It also participates in signal transduction by associating with lipid rafts and interacting with various signaling molecules upon specific stimuli, influencing T cell co-stimulation and adhesion.
• Role in TME: Protects host cells from complement-mediated lysis. Its expression on normal CD4+ T cells contributes to immune homeostasis. Its absence or reduction in tumor T cells might alter local immune responses or reflect a different T cell subset.
• Therapeutic Potential: While primarily a complement regulator, its role in T cell modulation could be exploited.
• Relevant Agents: No direct cancer therapeutic agents targeting CD55.
• Reference: UniProt: CD55

ATP1A1 (Na+/K+ ATPase alpha-1 subunit):

• Signaling Pathways: ATP1A1 is a catalytic subunit of the Na+/K+-ATPase pump, essential for maintaining cellular ion gradients. Beyond its pump function, it can act as a receptor, initiating signal transduction cascades involving Src kinases and MAPK pathways, influencing cell growth, differentiation, and apoptosis.
• Role in TME: Critical for maintaining cellular homeostasis and viability. Its specific role in CD4+ T cell fate in cancer is complex; alterations could reflect metabolic stress or changes in cell volume regulation in the TME.
• Therapeutic Potential: Cardiotonic steroids (e.g., digoxin) are known inhibitors of Na+/K+-ATPase, which have been explored for anti-cancer effects, but their T cell-specific impact needs careful consideration.
• Reference: PubMed search: ATP1A1 cancer T cell

ADGRE5 (CD97):

• Signaling Pathways: An adhesion G protein-coupled receptor (aGPCR), ADGRE5 is involved in cell-cell adhesion and migration. It can signal through its intracellular domain upon ligand binding, influencing cell motility and differentiation.
• Role in TME: CD97 is expressed on various immune cells and its ligands (e.g., CD55) are found on other cells. Its role in the TME is complex, potentially influencing immune cell trafficking or interactions with tumor cells.
• Therapeutic Potential: Due to its role in adhesion and migration, CD97 could be a target to modulate immune cell infiltration.
• Relevant Agents: Under investigation, but no approved agents.
• Reference: GeneCards: ADGRE5

TRAT1 (T-cell receptor-associated transmembrane adapter 1):

• Signaling Pathways: TRAT1 is an adapter protein involved in T-cell receptor (TCR) signaling. It plays a role in coupling the TCR complex to downstream signaling pathways, including those involving ZAP-70 and LAT, which are crucial for T cell activation.
• Role in TME: Essential for proper TCR signaling and T cell activation. Its higher expression in normal tissue CD4+ T cells suggests a more competent state for initiating immune responses, which might be compromised in the TME.
• Therapeutic Potential: Targeting adapter proteins like TRAT1 could modulate T cell sensitivity, but direct targeting is challenging due to potential broad immune effects.
• Reference: UniProt: TRAT1

• (Note: MYADM, PTGIR, GLIPR1, although detected as markers, have less extensively characterized roles in CD4+ T cell function within the tumor microenvironment compared to other listed markers. Their specific signaling pathways and therapeutic potential in this context require further investigation.)*

Markers Enriched in 'Tumor' CD4+ T cells

These markers are indicative of CD4+ T cell activation, exhaustion, or specific differentiation states within the tumor microenvironment, reflecting adaptations to the cancerous milieu or an active anti-tumor response that may be suppressed.

CD74 (MHC class II invariant chain):

• Signaling Pathways: CD74 is the invariant chain associated with MHC class II molecules, guiding their assembly and transport. It also acts as a receptor for macrophage migration inhibitory factor (MIF), initiating signaling pathways that can promote cell survival and proliferation, and influencing immune responses.
• Role in TME: Upregulation on CD4+ T cells in the TME might indicate increased MHC class II trafficking or response to MIF. MIF-CD74 signaling can promote inflammation and tumor progression, and its expression on T cells might contribute to a pro-tumorigenic inflammatory state or T cell activation.
• Therapeutic Potential: Blocking MIF-CD74 interaction could modulate immune responses and inhibit tumor growth.
• Relevant Agents: MIF inhibitors are under investigation, but specific CD74-targeting agents for T cells in cancer are not yet widespread.
• Reference: GeneCards: CD74

LY6E:

• Signaling Pathways: LY6E is a GPI-anchored protein involved in cell surface signaling. While its precise signaling pathways are not fully elucidated, it has been implicated in modulating receptor signaling, including TCR signaling, and influencing cell proliferation and differentiation.
• Role in TME: LY6E is often upregulated in various cancers and can contribute to immune evasion and tumor progression. Its expression on CD4+ T cells in the TME might indicate a specific functional state or subset that could be more amenable to exhaustion or immune suppression.
• Therapeutic Potential: Targeting LY6E could interfere with tumor immune evasion mechanisms or alter T cell function in the TME.
• Relevant Agents: No approved therapeutic agents.
• Reference: PubMed search: LY6E tumor immune evasion

TNFRSF4 (OX40):

• Signaling Pathways: OX40 (CD134) is a co-stimulatory receptor belonging to the TNFR superfamily. Upon binding to its ligand OX40L (TNFSF4) on APCs, it activates signaling pathways (e.g., NF-κB, PI3K/Akt) that promote T cell survival, proliferation, and cytokine production, especially of effector and memory CD4+ T cells.
• Role in TME: OX40 is expressed on activated CD4+ T cells (and CD8+ T cells) and is crucial for sustaining anti-tumor immune responses. Its upregulation indicates T cell activation within the TME, representing potential for immune boosting.
• Therapeutic Potential: OX40 agonists are being developed to enhance anti-tumor immunity by promoting the expansion and survival of tumor-specific T cells.
• Relevant Agents: Several anti-OX40 agonistic antibodies (e.g., MEDI6469, MOXR0916) are in clinical trials for various cancers.
• Reference: PubMed search: OX40 colorectal cancer immunotherapy

TNFRSF18 (GITR):

• Signaling Pathways: GITR (CD357) is another co-stimulatory receptor in the TNFR superfamily, expressed on activated T cells and especially highly on regulatory T cells (Tregs). Ligation by GITRL (TNFSF18) enhances effector T cell function and can overcome Treg-mediated suppression. It signals via TRAF proteins, activating NF-κB and MAPK pathways.
• Role in TME: Its expression suggests a population of activated or regulatory CD4+ T cells. In the TME, GITR activation can promote anti-tumor responses by enhancing effector T cell activity and/or by reducing the suppressive function of Tregs.
• Therapeutic Potential: GITR agonists are promising candidates for cancer immunotherapy, aiming to activate effector T cells and/or modulate Treg function.
• Relevant Agents: Agonistic anti-GITR antibodies (e.g., TRX518, MK-1248) are in clinical development.
• Reference: PubMed search: GITR colorectal cancer immunotherapy

TIGIT:

• Signaling Pathways: TIGIT (T cell Immunoreceptor with Ig and ITIM domains) is an inhibitory immune checkpoint receptor, expressed on T cells and NK cells. It binds to poliovirus receptor (PVR/CD155) and NECTIN2 (CD112) on APCs and tumor cells. TIGIT transduces inhibitory signals via its ITIM domain, suppressing T cell activation, proliferation, and cytokine production. It also directly competes with the activating receptor CD226 (DNAM-1).
• Role in TME: TIGIT is a key player in immune evasion in various cancers, including colorectal cancer. Its high expression on CD4+ T cells in the TME suggests an exhausted or suppressed phenotype, contributing to tumor immune tolerance.
• Therapeutic Potential: TIGIT is a high-priority therapeutic target. Blocking TIGIT aims to unleash anti-tumor immunity by relieving inhibitory signals and potentially enhancing CD226-mediated co-stimulation.
• Relevant Agents: Several anti-TIGIT monoclonal antibodies (e.g., Tiragolumab, Ociperlimab, Vibostolimab) are in clinical trials, often in combination with anti-PD-1/PD-L1 antibodies.
• Reference: PubMed search: TIGIT colorectal cancer immunotherapy

TNFRSF25 (DR3):

• Signaling Pathways: DR3 (Death Receptor 3) is a member of the TNFR superfamily. Its ligand, TL1A (TNFSF15), can mediate both T cell apoptosis (via FADD/caspase activation) and T cell costimulation/survival (via TRAF pathways and NF-κB activation), depending on the context and cell type. It is particularly important for homeostatic proliferation of memory T cells and can promote Th17 differentiation.
• Role in TME: The role of DR3 in TME is complex, influencing both pro- and anti-tumor immunity. Its expression on tumor-infiltrating CD4+ T cells may indicate a population primed for activation or apoptosis, potentially contributing to inflammation or immune evasion.
• Therapeutic Potential: Modulating DR3 signaling could offer therapeutic avenues to enhance anti-tumor responses, although the dual nature of its signaling requires careful consideration.
• Relevant Agents: Preclinical studies are exploring DR3 agonists or antagonists, but no approved agents are yet available.
• Reference: GeneCards: TNFRSF25

HLA-DPB1 and HLA-DPA1 (MHC Class II molecules):

• Signaling Pathways: HLA-DPB1 and HLA-DPA1 form the alpha and beta chains of the HLA-DP MHC class II heterodimer. MHC class II molecules present exogenous peptide antigens to CD4+ T cells, leading to TCR engagement and downstream signaling pathways that initiate T cell activation, proliferation, and differentiation.
• Role in TME: The expression of MHC class II molecules on CD4+ T cells (which are not canonical antigen-presenting cells) can indicate T cell activation or specific subsets with antigen-presenting capabilities (e.g., activated T cells or regulatory T cells). Their upregulation in the TME might reflect increased antigen processing and presentation by other cells in the TME, leading to T cell activation, or could suggest a subset of CD4+ T cells capable of 'reverse' antigen presentation, contributing to chronic inflammation or immune regulation.
• Therapeutic Potential: While MHC class II itself is not a direct therapeutic target, its expression levels reflect the antigen presentation machinery and T cell engagement. Strategies to enhance MHC class II expression on tumor cells or APCs could improve anti-tumor responses.
• Relevant Agents: Not directly targeted, but enhancing antigen presentation is a core strategy in cancer vaccines and adoptive cell therapies.
• Reference: UniProt: HLA-DPB1, UniProt: HLA-DPA1

Clinical or Translational Implications

The differential expression of surfaceome markers on CD4+ T cells between normal and tumor colon tissue highlights significant shifts in T cell phenotype and function in the colorectal cancer microenvironment.

1. Biomarker Discovery: The identified markers could serve as biomarkers to distinguish between healthy and tumor-infiltrating CD4+ T cell populations, potentially aiding in diagnosis, prognosis, or monitoring treatment response in colorectal cancer.
2. Therapeutic Targeting:
   • Immune Checkpoint Blockade: The high expression of inhibitory receptors like TIGIT on tumor-infiltrating CD4+ T cells presents a clear rationale for immune checkpoint blockade strategies in colorectal cancer. Combination therapies with anti-PD-1/PD-L1 agents could enhance anti-tumor efficacy.
   • Co-stimulatory Agonists: The upregulation of co-stimulatory receptors like OX40 and GITR suggests that a population of activated T cells exists within the TME, which could be further exploited by agonistic antibodies to boost anti-tumor immunity.
   • Metabolic Reprogramming: The lower expression of GLUT3 (SLC2A3) in tumor T cells, if indicative of metabolic suppression, points towards potential strategies to restore T cell metabolic fitness in the TME.
3. Understanding T cell Dysfunction: Markers like TIGIT strongly indicate T cell exhaustion. Strategies to reverse this exhaustion, beyond direct checkpoint blockade, are critical. The loss of markers found in normal tissue might also point to altered homing or differentiation pathways that could be restored.
4. Implications for Cell Therapy: Characterizing the surfaceome markers of tumor-infiltrating CD4+ T cells could inform the design of adoptive cell therapies, allowing for selection of T cell subsets with desirable phenotypes or engineering T cells with enhanced tumor-killing capabilities and resistance to TME-induced suppression.

Further research focusing on the functional consequences of these marker expression patterns through *in vitro* validation and *in vivo* models is warranted to fully elucidate their therapeutic potential in colorectal cancer.

19. Elevated Cell Cycle Gene Expression Fraction in Intestinal Epithelial Cells of Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the "expressing cell fraction (sample)" for a curated set of cell cycle pathway genes within Intestinal Epithelial cells, comparing samples from "Tumor" conditions against "Adj_normal" (adjacent normal) conditions. The goal is to identify genes exhibiting statistically significant differences in the proportion of cells expressing them between these two conditions, thereby providing insights into cell cycle regulation in colorectal cancer. The results are visualized using box plots, with significance indicated by p-values.

Visual Summary

The visualization presents 24 box plots, each representing a distinct cell cycle gene. In every plot, the "expressing cell fraction (sample)" is significantly higher in the "Tumor" condition (orange boxes) compared to the "Adj_normal" condition (blue boxes). The p-values displayed above each comparison are extremely low (all in the range of e-08 to e-10), indicating highly statistically significant differences.

Key visual observations include:

• Consistent Upregulation: For all 24 genes shown, the median expressing cell fraction is markedly elevated in tumor samples. This suggests a widespread increase in the proportion of Intestinal Epithelial cells actively expressing these cell cycle genes in the tumor microenvironment.
• Clear Separation: The box plots for "Tumor" and "Adj_normal" conditions show substantial separation, with minimal to no overlap in their interquartile ranges (IQR) for most genes, reinforcing the robust nature of the observed differences.
• Variability: While the overall trend is clear, the spread of the data points (individual samples) within the "Tumor" group appears more variable for some genes compared to the "Adj_normal" group, potentially reflecting heterogeneity in tumor samples.

Biological Interpretation

The observed increase in the "expressing cell fraction (sample)" for a broad panel of cell cycle genes in Intestinal Epithelial cells from tumor tissues strongly indicates heightened proliferative activity in colorectal cancer. Intestinal Epithelial cells are identified as the tumor-origin cell type, making these findings directly relevant to cancer progression.

Several key genes and their implications are noteworthy:

• Cell Cycle Regulators: Genes like MAD2L2 (Mitotic Arrest Deficient 2 Like 2) and FZR1 (Fizzy Related 1, also known as CDH1), involved in mitotic spindle checkpoint and APC/C activation, respectively, show significantly higher expression fractions in tumor. This points to active progression through mitosis. GeneCards: MAD2L2, GeneCards: FZR1
• DNA Replication Initiation: ORC2 and ORC4 (Origin Recognition Complex subunits 2 and 4) are crucial for initiating DNA replication. Their elevated expression fraction signifies an increased number of cells entering or actively engaged in the S-phase of the cell cycle. GeneCards: ORC2
• Cyclins and CDKs: CCND1 (Cyclin D1) and CCND3 (Cyclin D3) are key regulators of the G1/S phase transition. Their increased expressing cell fraction is a classic hallmark of uncontrolled cell proliferation and is often associated with cancer development. GeneCards: CCND1
• Anaphase-Promoting Complex (APC/C) Components: Genes like ANAPC1, ANAPC10, ANAPC11, ANAPC13, ANAPC7, and CDC26 are all subunits of the APC/C, a ubiquitin ligase that targets cell cycle proteins for degradation, enabling anaphase onset and exit from mitosis. Their increased expression fraction suggests active cell cycle machinery. GeneCards: ANAPC1
• Other Cell Cycle Effectors: PTTG1 (Pituitary Tumor-Transforming Gene 1), a securin, and CDC25B (Cell Division Cycle 25B), a phosphatase activating CDKs, are crucial for proper cell division and are upregulated in many cancers. MYC is a powerful oncogene that drives cell proliferation, and its increased expression is a strong indicator of cancer. RB1 (Retinoblastoma 1) is a tumor suppressor, and its increased *expression fraction* in tumor cells, alongside other proliferation markers, could reflect either dysregulation, a compensatory mechanism, or a state where its inhibitory function is overridden by other oncogenic signals in a greater proportion of cells. HDAC2 (Histone Deacetylase 2) is involved in epigenetic regulation and frequently promotes cell proliferation and survival in cancer. GeneCards: PTTG1, GeneCards: MYC

Collectively, these findings demonstrate that a higher proportion of Intestinal Epithelial cells within tumor samples are actively engaged in the cell cycle, supporting the well-established characteristic of uncontrolled proliferation in colorectal cancer.

Clinical or Translational Implications

The widespread and statistically significant upregulation of cell cycle pathway genes in tumor-derived Intestinal Epithelial cells has several potential clinical and translational implications:

• Biomarkers for Proliferation: The genes identified in this analysis could serve as robust biomarkers for assessing the proliferative status of colorectal cancer. Their high expressing cell fraction in tumor samples suggests potential utility in diagnosis, determining tumor aggressiveness, or monitoring treatment response.
• Therapeutic Targets: Many of the identified genes represent established or emerging therapeutic targets. For instance, CDK inhibitors targeting G1/S transition (e.g., related to CCND1/CCND3), MYC inhibitors, or HDAC inhibitors (e.g., targeting HDAC2) could be relevant therapeutic strategies to halt uncontrolled proliferation in colorectal cancer. PubMed Search: "colorectal cancer CDK inhibitors"
• Understanding Resistance: Characterizing the specific cell cycle pathways predominantly activated could also help in understanding mechanisms of resistance to current therapies and developing more targeted approaches.
• Prognostic Indicators: The degree of "expressing cell fraction" for these genes might correlate with patient prognosis, potentially identifying patients at higher risk of aggressive disease or recurrence.

These results underscore the importance of cell cycle dysregulation in colorectal cancer pathology and highlight candidate genes for further investigation as diagnostic, prognostic, or therapeutic targets.

20. Gene Ontology (GSA) Analysis for Intestinal Epithelial Cells

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Ontology (GO) enrichment results, specifically Gene Set Analysis (GSA), for Intestinal Epithelial cells. The analysis identifies biological pathways and processes that are significantly upregulated in specific conditions or cell states compared to "others" within the dataset. Three distinct comparisons were performed:

1. Adjacent Normal vs. Others: Upregulated pathways in Intestinal Epithelial cells from adjacent normal tissue.
2. Diploid vs. Others: Upregulated pathways in Intestinal Epithelial cells identified as diploid.
3. Tumor vs. Others: Upregulated pathways in Intestinal Epithelial cells from tumor tissue.

The bar plots display the statistical significance of enrichment for each GO term, represented by the negative logarithm of the p-value (-log(p-val)) and adjusted p-value (-log(q-val)). Higher values indicate greater significance.

Visual Summary

The provided bar plots illustrate the top enriched Gene Ontology terms based on upregulated differentially expressed genes (DEGs) in Intestinal Epithelial cells across three different comparison contexts.

• Adjacent Normal (Adj_normal_vs_others): This plot reveals a strong enrichment for metabolic pathways. Terms like "Fatty acid degradation," "Valine, leucine and isoleucine degradation," "Synthesis and degradation of ketone bodies," "Butanoate metabolism," and "Oxidative phosphorylation" are highly significant. Signaling pathways such as "PPAR signaling pathway" and "TGF-beta signaling pathway" also appear. These suggest an active role in nutrient processing and cellular homeostasis.
• Diploid (Diploid_vs_others): This plot shows a distinct profile, with "Ribosome" being the most significantly enriched term, followed by immune and infection-related pathways. These include "Coronavirus disease," "Toll-like receptor signaling pathway," "Viral protein interaction with cytokine and cytokine receptor," "NF-kappa B signaling pathway," and "Chemokine signaling pathway." The presence of several cancer-related terms (e.g., "Non-small cell lung cancer," "Glioma," "Breast cancer") is also notable, though less specific to the colon.
• Tumor (Tumor_vs_others): This plot displays the broadest and most highly significant enrichment. Explicit cancer-related terms such as "Colorectal cancer" and "Pathway, in cancer" are among the most prominent. Other highly enriched terms span core cellular processes like "Protein processing in endoplasmic reticulum," "Spliceosome," "Ribosome," "RNA transport," and "Cell cycle." Metabolic pathways (e.g., "mTOR signaling pathway," "AMPK signaling pathway," "Insulin signaling pathway," "Oxidative phosphorylation") are also highly represented. Furthermore, a remarkable number of infection-related pathways (bacterial and viral) and neurodegenerative disease pathways are enriched.

Biological Interpretation

The GSA results for Intestinal Epithelial cells provide critical insights into the biological state shifts occurring in the context of colorectal cancer.

• Adjacent Normal Intestinal Epithelial Cells: The prominent enrichment of metabolic pathways (e.g., fatty acid, amino acid, ketone body degradation) and oxidative phosphorylation in adjacent normal cells suggests a healthy, energy-producing phenotype. These cells are likely engaged in their normal physiological functions of nutrient absorption and maintaining tissue integrity, relying on efficient catabolism for energy. The "PPAR signaling pathway" plays a key role in lipid metabolism and energy homeostasis 1.
• Diploid Intestinal Epithelial Cells: The strong enrichment of "Ribosome" indicates active protein synthesis, which is fundamental for cell maintenance and growth. The co-enrichment of numerous immune and viral response pathways (e.g., Toll-like receptor, NF-kappa B, Chemokine signaling, various viral infection terms) suggests that even diploid epithelial cells, which are not aneuploid, may be actively sensing and responding to their microenvironment, potentially indicating ongoing immune surveillance or a basal level of inflammatory signaling. The presence of non-colorectal cancer terms could imply shared fundamental mechanisms or a broader cellular stress response.
• Tumor Intestinal Epithelial Cells: This condition shows a profound shift in cellular biology, consistent with oncogenic transformation:
  • Direct Cancer Link: The highly significant enrichment of "Colorectal cancer" and "Pathway, in cancer" terms directly validates the tumor-specific nature of these cells and the relevance of the inferred disease context.
  • Enhanced Proliferation and Anabolism: Pathways like "Cell cycle," "Ribosome," "Protein processing in endoplasmic reticulum," "RNA transport," "Proteasome," and "Lysosome" are highly active. This reflects the increased protein synthesis, degradation, and cellular machinery required to support rapid proliferation and growth characteristic of cancer cells.
  • Metabolic Reprogramming: The enrichment of "mTOR signaling pathway," "AMPK signaling pathway," and "Insulin signaling pathway" points to significant alterations in nutrient sensing and energy metabolism, often seen in cancer cells to fuel their rapid growth and survival 2. "Oxidative phosphorylation" also remains active, suggesting a complex metabolic landscape beyond the classical Warburg effect.
  • Immune and Inflammatory Environment: The striking enrichment of numerous infection-related pathways (e.g., Salmonella, Epstein-Barr virus, Human papillomavirus, Coronavirus, Pathogenic Escherichia coli) and "TNF signaling pathway" is highly significant. This suggests that the tumor microenvironment in colorectal cancer is characterized by chronic inflammation and/or a dysregulated host-pathogen interaction, which are known drivers of colorectal cancer progression 3. This could also indicate altered barrier function, facilitating microbial interaction, or an adaptive immune response within the tumor.
  • Cell Adhesion and Junctions: The presence of "Adherens junction" and "Tight junction" pathways suggests dysregulation of cell-cell contacts, which is crucial for epithelial tissue integrity and often perturbed during cancer invasion and metastasis.
  • Stress Response and Protein Homeostasis: Pathways like "Autophagy" and "Ubiquitin mediated proteolysis" highlight the cell's response to stress and its efforts to maintain protein quality, which can be hijacked by cancer cells for survival. The appearance of several neurodegenerative disease pathways might indicate shared mechanisms of protein misfolding or cellular stress responses that are broadly dysregulated in tumor cells.

Clinical or Translational Implications

The GSA findings for Intestinal Epithelial cells in colorectal cancer hold several clinical and translational implications:

• Biomarker Discovery: The highly enriched cancer-specific and metabolism-related pathways in tumor cells could yield novel biomarkers for early detection, prognosis, or monitoring treatment response in colorectal cancer.
• Therapeutic Targets: Pathways such as mTOR, AMPK, and Insulin signaling, along with those involved in protein processing (ER, ribosome), are known targets in cancer therapy. The specific dysregulation observed here could guide the development or repurposing of targeted therapies for colorectal cancer patients.
• Immunomodulation and Microbiome: The strong signature of immune and infection-related pathways in tumor epithelial cells underscores the critical role of inflammation and the gut microbiome in colorectal cancer. This suggests potential therapeutic strategies involving immunomodulation, targeting specific microbial pathways, or understanding pathogen-driven oncogenesis.
• Understanding Tumor Microenvironment: The distinct profiles between adjacent normal, diploid, and tumor cells provide a foundation for understanding the complex interplay between different cell states and the tumor microenvironment, which is essential for developing comprehensive treatment strategies.

References:

1. PPAR Signaling Pathway - GeneCards
2. Metabolic reprogramming in cancer: an updated overview
3. The role of inflammation in colorectal cancer

21. Gene Set Enrichment Analysis (GSEA) of Colorectal Cancer Cell Types

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results visualized as a dot plot. It highlights pathways and biological processes that are significantly enriched or suppressed across various celltype_minor populations, comparing their expression profiles in different conditions. Specifically, the comparisons are made between cells in the 'Tumor' condition versus 'Adj_normal' (referenced as 'others' in the plot for brevity) for most cell types, and also for 'Diploid' Intestinal Epithelial cells versus 'others' within the Intestinal Epithelial cell population. The dot size represents the significance of enrichment (-log(p-value)), while the color indicates the Normalized Enrichment Score (NES), where red signifies positive enrichment (upregulation) and blue signifies negative enrichment (downregulation). The analysis aims to uncover condition-specific biological shifts in colorectal cancer at a single-cell resolution.

Visual Summary

The dot plot effectively visualizes the landscape of enriched pathways across nine key cell types (B cell, Endothelial cell, Fibroblast, ILC, Intestinal Epithelial cell, Macrophage, Plasma cell, T cell CD4+, T cell CD8+) under 'Tumor' and 'Adj_normal' conditions (and 'Diploid' for Intestinal Epithelial cells).

• Overall Pattern: A clear pattern of strong positive enrichment (large red dots) for numerous pathways is observed primarily in cells from the 'Tumor_vs_others' comparisons, especially within Intestinal Epithelial cells, Fibroblasts, Endothelial cells, and Macrophages. Conversely, these same pathways often show negative enrichment (blue dots) or no significant enrichment in the 'Adj_normal_vs_others' comparisons.
• Cancer-Specific Pathways: Pathways directly related to cancer, such as "Pathways in cancer", "Colorectal cancer", "Transcriptional misregulation in cancer", "VEGF signaling pathway", and "Wnt signaling pathway", are prominently and strongly enriched (large red dots) across multiple cell types in the 'Tumor_vs_others' condition. This enrichment is most pronounced in Intestinal Epithelial cells, Fibroblasts, Endothelial cells, and Macrophages.
• Metabolic Reprogramming: Several metabolic pathways, including "Glycolysis / Gluconeogenesis", "Biosynthesis of unsaturated fatty acids", and "Cholesterol metabolism", show widespread positive enrichment in 'Tumor_vs_others' comparisons across almost all cell types analyzed, indicative of altered metabolism in the tumor microenvironment.
• Cellular Growth and Maintenance: Pathways related to cellular machinery and proliferation, such as "Protein processing in endoplasmic reticulum", "Ribosome biogenesis in eukaryotes", "RNA transport", and "Lysosome", are consistently enriched in tumor-associated Intestinal Epithelial cells, Fibroblasts, Endothelial cells, and Macrophages.
• Immune Cell Specificity: Immune cells (B cell, Macrophage, T cell CD4+, T cell CD8+, ILC, Plasma cell) in the 'Tumor_vs_others' condition show enrichment for general cancer pathways and metabolic reprogramming. Specific immune response pathways also show differential enrichment; for instance, "Antigen processing and presentation" is enriched in tumor Macrophages and B cells. In contrast, "T cell receptor signaling pathway" and "Th1 and Th2 cell differentiation" show negative enrichment (blue dots) in tumor T cells, while "Th17 cell differentiation" is positively enriched in tumor T cell CD4+.

Biological Interpretation

The GSEA results provide strong biological insights into the molecular changes occurring within the colorectal cancer (CRC) tumor microenvironment.

General Cancer Hallmarks

The pervasive enrichment of core cancer pathways ("Pathways in cancer", "Colorectal cancer", "Transcriptional misregulation in cancer", "Wnt signaling pathway", "VEGF signaling pathway", "PI3K-Akt signaling pathway") across tumor-associated Intestinal Epithelial cells, Fibroblasts, Endothelial cells, and Macrophages directly reflects the multi-cellular nature of cancer progression. This indicates that the tumor-driving genetic alterations not only affect the epithelial cells of origin but also induce significant transcriptional reprogramming in the surrounding stromal and immune components, creating a supportive tumor microenvironment.

Cell-type Specific Roles in Tumor Microenvironment

• Intestinal Epithelial Cells (Tumor Core): The Intestinal Epithelial cell: Tumor_vs_others comparison shows the most profound enrichment of proliferative, metabolic, and signaling pathways critical for cancer growth, such as "Glycolysis / Gluconeogenesis", "Wnt signaling pathway", and "PI3K-Akt signaling pathway". The enrichment of these pathways even in Intestinal Epithelial cell: Diploid_vs_others suggests that even diploid epithelial cells within the tumor context may exhibit early tumor-promoting changes or respond to signals from the aneuploid tumor cells.

Stromal Cells (Fibroblasts, Endothelial Cells):

• Fibroblasts: Strong enrichment of cancer-related pathways and those associated with extracellular matrix remodeling ("RNA transport", "Protein processing in endoplasmic reticulum") in Fibroblast: Tumor_vs_others suggests the activation of cancer-associated fibroblasts (CAFs). CAFs are known to promote tumor growth, invasion, and metastasis in CRC by secreting growth factors and remodeling the extracellular matrix GeneCards: FAP.
• Endothelial Cells: The high enrichment of "VEGF signaling pathway", "PI3K-Akt signaling pathway", and metabolic pathways in Endothelial cell: Tumor_vs_others is a hallmark of tumor angiogenesis, the formation of new blood vessels essential for tumor growth and metastasis in CRC PubMed search: VEGF signaling colorectal cancer angiogenesis.

Immune Cells (Macrophages, T cells, B cells, Plasma cells, ILCs):

• Macrophages: The significant enrichment of "Pathways in cancer", "VEGF signaling pathway", "Wnt signaling pathway", and "Antigen processing and presentation" in Macrophage: Tumor_vs_others is consistent with the role of tumor-associated macrophages (TAMs). TAMs can exert both anti-tumor and pro-tumor effects, but in many cancers, they often adopt a pro-tumorigenic M2-like phenotype, contributing to immunosuppression, angiogenesis, and tumor progression GeneCards: CD68. Their enrichment in "Phagosome" and "Lysosome" pathways suggests active cellular processing.
• T cells (CD4+ and CD8+): While showing some general cancer pathway enrichment, the negative enrichment of "T cell receptor signaling pathway" and "Th1 and Th2 cell differentiation" in tumor T cells suggests T cell anergy or exhaustion, a common mechanism of immune evasion by tumors. Conversely, the positive enrichment of "Th17 cell differentiation" in T cell CD4+: Tumor_vs_others is notable, as Th17 cells can promote inflammation and tumor progression in CRC PubMed search: Th17 colorectal cancer tumor progression.
• B cells, Plasma cells, ILCs: These cell types also show metabolic reprogramming and involvement in general cancer pathways within the tumor microenvironment, indicating a broad systemic impact of the tumor on various immune populations. Plasma cells show strong enrichment of "Protein processing in endoplasmic reticulum", consistent with their function in antibody secretion.

Metabolic Reprogramming

The consistent enrichment of "Glycolysis / Gluconeogenesis" across nearly all tumor-associated cell types underscores the metabolic plasticity and the "Warburg effect" in the CRC tumor microenvironment. Cancer cells preferentially utilize glycolysis even in the presence of oxygen, and this metabolic shift extends to stromal and immune cells, supporting rapid proliferation and biomass accumulation PubMed search: Warburg effect colorectal cancer. Pathways like "Biosynthesis of unsaturated fatty acids" and "Cholesterol metabolism" further highlight altered lipid metabolism, critical for membrane synthesis and signaling in rapidly dividing cells.

Immune Dysregulation

The differential enrichment of immune-related pathways in T cells, with signs of T cell exhaustion or altered differentiation (e.g., negative enrichment of Th1/Th2 differentiation, positive enrichment of Th17 differentiation), points towards significant immune dysregulation within the CRC microenvironment. The active "Antigen processing and presentation" in macrophages and B cells might indicate attempts at immune response or, conversely, mechanisms employed by the tumor to present altered antigens and evade effective immune attack.

Clinical or Translational Implications

The comprehensive GSEA results provide several potential clinical and translational implications for colorectal cancer:

• Therapeutic Targets: Pathways consistently enriched across multiple tumor-associated cell types, such as "Wnt signaling pathway", "VEGF signaling pathway", "PI3K-Akt signaling pathway", and central metabolic pathways like "Glycolysis / Gluconeogenesis", represent attractive targets for multi-modal therapies. Targeting these pathways could inhibit tumor growth, angiogenesis, and metabolic support within the tumor microenvironment.
• Biomarkers: Specific pathway enrichments in different cell populations could serve as prognostic biomarkers or indicators of response to therapy. For example, specific gene signatures derived from the enriched pathways in CAFs or TAMs could indicate aggressive disease or resistance mechanisms.
• Immune Checkpoint Strategies: The observed T cell exhaustion (negative enrichment of T cell receptor signaling) and altered T cell differentiation (Th17 enrichment) provide a rationale for exploring immune checkpoint blockade therapies or adoptive cell therapies to reprogram T cell responses in CRC PubMed search: T cell exhaustion colorectal cancer immunotherapy.
• Understanding Heterogeneity: The cell-type-specific pathway enrichments highlight the importance of single-cell resolution in understanding the complex and heterogeneous tumor microenvironment. Therapeutic strategies might need to be tailored not just to the tumor cells, but also to the specific stromal and immune cell populations that actively contribute to disease progression.

22. Discussion

This comprehensive single-cell analysis of human colon tissue elucidates the multifaceted landscape of colorectal cancer (CRC), integrating genomic, transcriptomic, and intercellular communication insights. The foundational observation is the striking genomic instability within Intestinal Epithelial cells from tumor samples, confirmed by widespread aneuploidy (22.6% of total cells) and recurrent copy number amplifications (e.g., EGFR, 8q21.1:8q24.1, 19p13:19q13.13). This firmly establishes the malignant identity of these epithelial cells and highlights key genomic drivers of CRC progression.

The tumor microenvironment (TME) undergoes a profound remodeling of its cellular composition. Intestinal Epithelial cells become dominant in tumor samples, directly reflecting neoplastic expansion. Critically, the immune landscape shifts towards an immunosuppressive state, marked by a significant increase in regulatory T cells (Tregs) and Th17 cells, alongside a decrease in ILC1 and LTI cells. Macrophages exhibit a distinct polarization switch, with M2B macrophages becoming highly enriched in tumors, accompanied by a modest increase in M1 macrophages, indicating a complex pro-tumorigenic and inflammatory milieu rather than a purely M2-dominant one. These shifts suggest active immune evasion mechanisms and altered immune cell function.

Cell-cell interaction (CCI) analysis reveals a dramatic rewiring of communication networks from normal tissue homeostasis to tumor-promoting crosstalk. Interactions prevalent in normal tissue, such as PGE2-PTGER4 and TRAIL-TRAILR2 signaling, are diminished in tumors. Conversely, tumor samples show robust activation of interactions critical for cancer hallmarks: extensive collagen-integrin interactions, VCAM1-integrin, and SPP1-integrin signaling drive extracellular matrix remodeling and cell migration; VEGFA-FLT1 (VEGFR1) promotes angiogenesis; CXCL12-CXCR4 orchestrates immune cell trafficking and tumor survival; and WNT2B-FZD1/LRP5 fuels proliferation. Alarmingly, key immune checkpoint (CD274/PD-L1-PDCD1/PD-1) and growth factor (EGFR ligands-EGFR) pathways are highly activated in the TME, alongside widespread TGF-beta signaling, collectively contributing to immune evasion, uncontrolled proliferation, and pro-fibrotic remodeling.

Specific surfaceome marker analyses further delineate the phenotypic adaptations of key cell types. Tumor-associated Intestinal Epithelial cells overexpress established targets like CEACAM5, EPCAM, and CD47, alongside potential novel targets such as DDR1, EPHA2, and MUC4, all implicated in promoting proliferation, invasion, and immune evasion. Macrophages in the TME acquire a distinct phenotype marked by GPNMB, AXL, NRP2, and CD36, reflecting their pro-angiogenic and immunosuppressive roles. Cancer-Associated Fibroblasts (CAFs) upregulate canonical markers like FAP, PDGFRB, and PLAUR, along with immune modulators like CD276 (B7-H3), underscoring their critical role in ECM remodeling and creating an immune-privileged niche. CD4+ T cells in tumors show a shift towards expression of activation/exhaustion markers (OX40, GITR, TIGIT) and MHC Class II molecules, indicative of an engaged but often suppressed or misdirected immune response.

Underpinning these changes, gene ontology and gene set enrichment analyses confirm pervasive metabolic reprogramming (e.g., glycolysis, lipid metabolism, mTOR signaling) and widespread activation of cell cycle machinery across tumor-associated cells. This concerted effort of multiple cell types to sustain rapid growth and adapt to the harsh TME is a defining characteristic of CRC. These multi-faceted findings collectively paint a detailed picture of the CRC microenvironment, offering a rich source for identifying novel biomarkers, validating existing therapeutic strategies, and developing next-generation targeted and immunotherapeutic interventions.

Hypotheses:

1. The observed expansion of regulatory T cells (Tregs) and M2B macrophages in the colorectal cancer microenvironment actively drives immune suppression, hindering effective anti-tumor T cell responses and promoting tumor progression.
2. Specific recurrent copy number amplifications, such as those involving EGFR and genes in the 8q21.1:8q24.1 region, act as key oncogenic drivers in Intestinal Epithelial cells, leading to their uncontrolled proliferation and malignant transformation in colorectal cancer.
3. The global shift in cell-cell interaction patterns within the tumor microenvironment, particularly the upregulation of growth factor (EGFR, Wnt, VEGF), extracellular matrix remodeling (integrins), and immune checkpoint (PD-L1-PD-1) pathways, directly facilitates tumor growth, invasion, angiogenesis, and immune evasion.
4. Overexpression of specific surfaceome markers on Cancer-Associated Fibroblasts (e.g., FAP, CD276) and Tumor-Associated Macrophages (e.g., GPNMB, AXL) are critical for their pro-tumorigenic functions and represent selective targets to therapeutically remodel the tumor microenvironment.
5. Metabolic reprogramming (e.g., increased glycolysis and altered lipid metabolism) and widespread activation of cell cycle regulatory genes are fundamental adaptations spanning multiple cell types in the colorectal cancer TME, acting as synergistic drivers of tumor progression.

Potential therapeutic targets:

1. PD-1/PD-L1 axis (PDCD1/CD274): Upregulated in tumor cells (aneuploid Intestinal Epithelial cells) and tumor-associated macrophages, this interaction suppresses T-cell mediated anti-tumor immunity by inducing T-cell anergy and exhaustion, a key mechanism of immune evasion. Evidence: CCI analysis (Section 14) shows strong CD274 (PD-L1) - PDCD1 (PD-1) interactions between Macrophages/Aneuploid Intestinal Epithelial cells and CD8+ T cells in tumor samples, significantly increased compared to adjacent normal tissue. Validation: Clinical trials with anti-PD-1/PD-L1 antibodies (e.g., Pembrolizumab, Nivolumab, Atezolizumab) are ongoing and approved for specific CRC patients (e.g., MSI-H). Further validation involves assessing response in patient cohorts based on expression levels and optimizing combination therapies.
2. EGFR (Epidermal Growth Factor Receptor): EGFR and its ligands are highly activated across tumor epithelial, stromal, and immune cells, driving cell proliferation, survival, migration, and angiogenesis. EGFR amplification is also recurrent in tumor epithelial cells. Evidence: CNV analysis (Section 4) identifies recurrent EGFR amplification in Intestinal Epithelial cells. CCI analysis (Section 14) shows significant increase in interactions between various EGF family ligands (AREG, HBEGF, EREG, TGFA, BTC) and EGFR on aneuploid Intestinal Epithelial cells, Fibroblasts, Endothelial cells, and Macrophages in tumor samples. Validation: Anti-EGFR monoclonal antibodies (e.g., Cetuximab, Panitumumab) are standard treatments for RAS wild-type metastatic CRC. Validation includes stratifying patients based on EGFR amplification/expression and exploring combination strategies to overcome resistance.
3. FAP (Fibroblast Activation Protein alpha): FAP is a canonical marker of activated Cancer-Associated Fibroblasts (CAFs), which extensively remodel the extracellular matrix, creating a desmoplastic and immunosuppressive tumor microenvironment that fosters tumor growth, invasion, and therapy resistance. Evidence: Surfaceome marker analysis (Section 17) demonstrates high mean expression and widespread prevalence of FAP in Fibroblasts from tumor samples, with minimal expression in adjacent normal tissue. Validation: FAP-targeted immunotherapies (e.g., CAR-T cells, bispecific antibodies, ADCs) and FAP enzymatic inhibitors are under investigation. Validation requires assessing the efficacy of these agents in preclinical models and clinical trials, particularly in combination with other therapies to disrupt the tumor stroma.
4. CD47 (CD47 Molecule): CD47 is a 'don't eat me' signal overexpressed on tumor cells, allowing them to evade phagocytosis by macrophages and escape innate immune surveillance. Evidence: Surfaceome marker analysis (Section 15) shows high mean expression and prevalence of CD47 on Intestinal Epithelial cells from tumor samples. Validation: Anti-CD47 antibodies and CD47-blocking agents are in clinical development for solid tumors, including CRC. Validation focuses on demonstrating enhanced phagocytosis of tumor cells, anti-tumor efficacy as monotherapy or in combination, and safety in patient cohorts.
5. TIGIT (T cell Immunoreceptor with Ig and ITIM domains): TIGIT is an inhibitory immune checkpoint receptor highly expressed on CD4+ T cells in the tumor microenvironment, contributing to T cell exhaustion and immune tolerance. Evidence: Surfaceome marker analysis (Section 18) reveals high expression of TIGIT on CD4+ T cells specifically in tumor samples, suggesting an exhausted or suppressed phenotype. Validation: Anti-TIGIT monoclonal antibodies (e.g., Tiragolumab) are in clinical trials, often combined with anti-PD-1/PD-L1 antibodies. Validation involves assessing the ability to unleash anti-tumor immunity, improve T cell function, and enhance clinical responses in CRC patients.
6. GPNMB (Glycoprotein Non-Metastatic B): GPNMB is highly expressed in tumor-associated macrophages (TAMs), which often adopt a pro-tumorigenic and immunosuppressive phenotype, promoting angiogenesis, tumor cell survival, and invasion. Evidence: Surfaceome marker analysis (Section 16) shows strong and specific upregulation of GPNMB in Macrophages from tumor samples, with minimal expression in normal tissue macrophages. Validation: GPNMB-targeting antibody-drug conjugates (ADCs) have been investigated in other cancers. Validation in CRC could involve demonstrating selective depletion or functional inhibition of GPNMB+ TAMs, leading to reduced tumor growth and enhanced anti-tumor immunity in preclinical models and early-phase clinical trials.
7. TGF-beta pathway (TGFB1/2/3 - TGFbeta_receptor1/2/3): TGF-beta signaling is highly active in the tumor microenvironment, acting as a tumor promoter by inducing epithelial-mesenchymal transition (EMT), promoting angiogenesis, and profoundly suppressing anti-tumor immunity through effects on T cells and other immune cells. Evidence: CCI analysis (Section 14) shows significant increase in interactions involving TGFB1, TGFB2, and TGFB3 with their receptors across aneuploid Intestinal Epithelial cells, Fibroblasts, Macrophages, and T cells in tumor samples. Validation: TGF-beta pathway inhibitors are under investigation in clinical trials for various cancers, including CRC, aiming to restore anti-tumor immunity and reduce fibrosis. Validation involves assessing immune reconstitution, reduction in fibrosis, and improved therapeutic efficacy, particularly in combination with immunotherapies.
8. VEGFA-FLT1 (VEGFR1) axis: VEGFA-FLT1 interaction is a hallmark of tumor angiogenesis, essential for providing oxygen and nutrients to rapidly growing tumors and facilitating metastasis. Evidence: CCI analysis (Section 13) demonstrates a strong VEGFA-FLT1 interaction, particularly between Endothelial cells and Fibroblasts or Intestinal Epithelial cells, highly activated in tumor samples. Validation: Anti-VEGF antibodies (e.g., Bevacizumab) or VEGFR inhibitors (e.g., Ramucirumab) are standard treatments for metastatic colorectal cancer. Validation involves monitoring anti-angiogenic effects, tumor growth inhibition, and patient survival, often in combination with chemotherapy.

Follow-up validation ideas:

1. Validate the altered proportions of Treg and M2B macrophage subsets identified by single-cell RNA-seq using flow cytometry or multiplex immunohistochemistry on independent colorectal cancer patient tissue samples.
2. Perform spatial transcriptomics or high-resolution multiplex immunofluorescence to confirm the spatial co-localization and functional interactions of identified ligand-receptor pairs (e.g., PD-L1-PD-1, VEGFA-FLT1) and their associated cell types within human colorectal cancer biopsies.
3. Conduct in vitro co-culture experiments using patient-derived tumor organoids, fibroblasts, macrophages, and T cells to functionally test specific cell-cell interactions. Use blocking antibodies or genetic perturbations (e.g., CRISPR knockout) to assess the impact on tumor cell proliferation, migration, immune cell activation, and suppression.
4. Employ CRISPR/shRNA-mediated knockdown or overexpression in colorectal cancer cell lines or patient-derived xenograft models to validate the functional roles of recurrently amplified genes (e.g., EGFR, TPD52) and highly expressed surface markers (e.g., MUC4, DDR1) in tumor growth, invasion, and metastatic potential.
5. Measure metabolic flux and key enzymatic activities using targeted metabolomics or reporter assays in isolated tumor-associated cell types (Intestinal Epithelial cells, Fibroblasts, Macrophages) to confirm the observed metabolic reprogramming, such as increased glycolysis and altered lipid metabolism.
6. Analyze independent cohorts of colorectal cancer patients (using bulk or single-cell sequencing, or tissue-based assays) to confirm the prognostic or predictive value of the identified immune cell ratios (e.g., Treg/CD8+ T cell ratio), pathway enrichments, and surface marker expression in relation to clinical outcomes and response to therapy.

Limitations:

The current single-cell RNA-sequencing analysis provides valuable insights into gene expression and inferred cell states, but it inherently relies on RNA-level data, which may not always directly correlate with protein expression or functional activity. Copy number variation estimates are based on scRNA-seq and represent inferential data, not high-resolution genomic sequencing. Cell-cell interaction predictions are derived from ligand-receptor expression and infer potential interactions, but do not confirm direct physical contact or functional signaling in vivo. Furthermore, the absence of comprehensive spatial information for all interactions limits the ability to confirm their in situ relevance. The inferred disease context is provisional and cannot determine specific disease subtype, stage, or prognosis. The generalizability of these findings may be constrained by the characteristics and sample size of the analyzed cohort. Therefore, further in vitro, in vivo, and clinical validation studies are essential to confirm the functional roles of identified markers and pathways, and to assess the therapeutic efficacy and safety of potential targets.

23. Query List

1. Show and save UMAPs for condition, sample, major cell type, minor cell type, ploidy_dec, and celltype_subset in two columns.
2. Show major cell type scores on UMAP and save the result.
3. Show and save a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values.
4. Select Intestinal Epithelial cells, show a CNV heatmap grouped by sample together with a summary of regions with significantly amplified copy numbers, and save the results.
5. Show and save UMAPs of CNV patterns colored by major cell type, minor cell type, ploidy results, condition, and sample in two columns.
6. Show and save a population bar plot of minor cell types.
7. Show and save a population bar plot of T cell subsets.
8. Show and save box plots of T cell subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
9. Show and save a population bar plot of macrophage subsets.
10. Show and save box plots of macrophage subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
11. Select Intestinal Epithelial cells, show their ploidy populations as a bar plot, and save the result.
12. Show and save cell-cell interaction patterns involving Intestinal Epithelial cells, fibroblasts, macrophages, T cells, and other relevant cell types. Select at most 80 cell-cell interactions per group.
13. Find cell-cell interactions involving Intestinal Epithelial cells, major immune and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms, its potential as a therapeutic target, and relevant therapeutic agents.
14. Find cell-cell interactions containing immune checkpoint and cell cycle pathway genes and involving Intestinal Epithelial cells, major immune and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms, its potential as a therapeutic target, and relevant therapeutic agents.
15. Show marker expressions for Intestinal Epithelial cells in a dot plot, and save the result. Use only surfaceome markers, with at most 60 markers per condition. For the markers identified under each condition, distinguish between established therapeutic targets and less well-characterized markers with potential as therapeutic targets. For each marker, using the provided dataset context, describe the associated signaling pathways and mechanisms, relevant therapeutic agents, and supporting evidence.
16. Show marker expressions for Macrophage in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
17. Show marker expressions for Fibroblast in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
18. Show marker expressions for T cell CD4+ in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
19. Among cell cycle pathway genes, select those with statistically significant expression differences between conditions in Intestinal Epithelial cells, show box plots, and save the result. Set max_n_items_to_plot to 24 and choose ncols based on the total number of panels for an overall width-to-height ratio of approximately 2:3.
20. Show and save Gene Ontology (GSA) analysis results for Intestinal Epithelial cells as a bar plot.
21. Show Gene Set Enrichment Analysis results as a dot plot, and save it. Set the color map to RdBu_r, n_pws_to_show to 120, and target_cells to None.